title,url,date,tags,excerpt
"Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody",https://www.merck.com/news/merck-closes-exclusive-global-license-agreement-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody/,2024-12-20T00:00:00,Licensing Agreement,
"Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection",https://www.merck.com/news/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-oral-two-drug-single-tablet-regimen-of-doravirine-islatravir-dor-isl-for-the-treatment-of-adults/,2024-12-19T00:00:00,Clinical trial update,
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist,https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-investigational-oral-glp-1-receptor-agonist/,2024-12-18T00:00:00,Licensing Agreement,
"Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season",https://www.merck.com/news/merck-announces-fda-acceptance-of-biologics-license-application-for-clesrovimab-an-investigational-long-acting-monoclonal-antibody-designed-to-protect-infants-from-rsv-disease-during-their-first-rsv/,2024-12-17T00:00:00,Regulatory approval,
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab,https://www.merck.com/news/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs-evaluating-investigational-vibostolimab-and-favezelimab-fixed-dose-combinations-with-pembrolizumab/,2024-12-16T00:00:00,Clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC",https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-after-surgery-as-adjuvant-treatment-for-patien/,2024-12-16T00:00:00,Regulatory approval,
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-welireg-belzutifan-as-treatment-for-adult-patients-with-certain-types-of-von-hippel-lindau-disease-associated-tumors-and-for-certain-previously-trea/,2024-12-13T00:00:00,Regulatory approval,
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial,https://www.merck.com/news/lynparza-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-3-trial/,2024-12-11T00:00:00,Clinical trial update,
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer,https://www.merck.com/news/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-advanced-epithelial-ovarian-cancer/,2024-12-09T00:00:00,Clinical trial update,
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma,https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in-phase-2-trial-of-previously-untreated-patients-with-diff/,2024-12-08T00:00:00,Clinical trial update,
"Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults",https://www.merck.com/news/merck-announces-positive-data-on-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-demonstrated-immune-responses-in-adults/,2024-03-19T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemoradiotherapy-crt-significantly-improved-overall-survival-os-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-ce/,2024-03-15T00:00:00,clinical trial update,
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9,https://www.merck.com/news/merck-announces-plans-to-conduct-clinical-trials-of-a-novel-investigational-multi-valent-human-papillomavirus-hpv-vaccine-and-single-dose-regimen-for-gardasil-9/,2024-03-13T00:00:00,clinical trial update,
"Merck Completes Acquisition of Harpoon Therapeutics, Inc.",https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/,2024-03-11T00:00:00,management update,
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24,https://www.merck.com/news/gilead-and-merck-announce-phase-2-data-showing-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-at-week-24/,2024-03-06T00:00:00,clinical trial update,
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-barclays-26th-annual-global-healthcare-conference/,2024-03-05T00:00:00,management update,
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024,https://www.merck.com/news/merck-to-participate-in-the-leerink-partners-global-biopharma-conference-2024/,2024-03-04T00:00:00,management update,
Merck to Participate in the TD Cowen 44th Annual Health Care Conference,https://www.merck.com/news/merck-to-participate-in-the-td-cowen-44th-annual-health-care-conference/,2024-02-27T00:00:00,management update,
"Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence",https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-the-treat/,2024-02-23T00:00:00,regulatory approval,
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma,https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-primary-advanced-or-recurrent-endometrial-carcinoma/,2024-02-20T00:00:00,regulatory approval,
Merck Animal Health to Acquire Elanco’s Aqua Business,https://www.merck.com/news/merck-animal-health-to-acquire-elancos-aqua-business-2/,2024-02-05T00:00:00,management update,
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results,https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/,2024-02-01T00:00:00,financial news,
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy,https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-the-risk-of-death-by-38-versus-placebo-as-adjuvant-therapy-for-patients-with-renal-cell-carcinoma-rcc-at-an-increased-risk-of-recurrence-follow/,2024-01-27T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery,https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-disease-free-survival-dfs-as-adjuvant-therapy-versus-observation-in-high-risk-patients-with-localized-muscle-invasive-and-locall/,2024-01-26T00:00:00,clinical trial update,
Merck Announces Second-Quarter 2024 Dividend,https://www.merck.com/news/merck-announces-second-quarter-2024-dividend/,2024-01-23T00:00:00,financial news,
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1,https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2023-sales-and-earnings-conference-call-feb-1/,2024-01-19T00:00:00,management update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemoradiotherapy-as-treatment-for-patients-with-figo-2014-stage-iii-iva-cervical-cancer/,2024-01-12T00:00:00,regulatory approval,
"Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline",https://www.merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/,2024-01-08T00:00:00,management update,
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline,https://www.merck.com/news/merck-announces-phase-3-trial-initiations-for-four-investigational-candidates-from-its-promising-hematology-and-oncology-pipeline/,2024-01-05T00:00:00,clinical trial update,
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference/,2024-01-03T00:00:00,management update,
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,https://www.merck.com/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer/,2023-12-22T00:00:00,regulatory approval,
Merck Provides U.S. Regulatory Update on Gefapixant,https://www.merck.com/news/merck-provides-u-s-regulatory-update-on-gefapixant/,2023-12-20T00:00:00,regulatory approval,
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference,https://www.merck.com/news/merck-to-participate-in-the-goldman-sachs-healthcare-c-suite-unscripted-conference/,2023-12-20T00:00:00,management update,
"FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults",https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults/,2023-12-19T00:00:00,regulatory approval,
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer,https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-for-new-first-line-indications-in-advanced-her2-negative-gastric-or-gej-adenocarcinoma-in-tumors-expressin/,2023-12-18T00:00:00,regulatory approval,
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer,https://www.merck.com/news/fda-approves-expanded-indication-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-adult-patients-with-locally-advanced-or-metastatic-uroth/,2023-12-15T00:00:00,regulatory approval,
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI,https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/,2023-12-14T00:00:00,regulatory approval,
Moderna and Merck Announce mRNA-4157 (V940) in Combination with KEYTRUDA® (pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years,https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-continued-improvement-in-recurrence-free-survival-and-distant-metastasis-free-survival-in-pa/,2023-12-14T00:00:00,clinical trial update,
Merck Ranks No. 1 on Newsweek’s List of America’s Most Responsible Companies 2024,https://www.merck.com/news/merck-ranks-no-1-on-newsweeks-list-of-americas-most-responsible-companies-2024/,2023-12-13T00:00:00,management update,
"Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer",https://www.merck.com/news/merck-and-moderna-initiate-interpath-002-a-phase-3-study-evaluating-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-certain-types-of-resect/,2023-12-11T00:00:00,clinical trial update,
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs,https://www.merck.com/news/merck-animal-health-receives-positive-cvmp-opinion-for-an-injectable-formulation-of-bravecto-fluralaner-for-use-in-dogs/,2023-12-11T00:00:00,regulatory approval,
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma,https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-001-trial-evaluating-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-patients-with-advanced-or-recurrent-endometrial-carcinom/,2023-12-08T00:00:00,clinical trial update,
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility,https://www.merck.com/news/merck-announces-keylynk-008-trial-evaluating-keytruda-pembrolizumab-plus-lynparza-olaparib-for-patients-with-metastatic-squamous-non-small-cell-lung-cancer-to-stop-for-futility/,2023-12-07T00:00:00,clinical trial update,
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC),https://www.merck.com/news/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an-investigational-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small-cell-lung/,2023-12-07T00:00:00,clinical trial update,
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer,https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-patients-with-locally-advanced/,2023-11-30T00:00:00,regulatory approval,
Merck Announces First-Quarter 2024 Dividend,https://www.merck.com/news/merck-announces-first-quarter-2024-dividend/,2023-11-28T00:00:00,financial news,
"Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older",https://www.merck.com/news/mercks-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults-demonstrated-superior-immunogenicity-for-10-of-11-unique-serotypes-compared/,2023-11-28T00:00:00,clinical trial update,
"Merck to Acquire Caraway Therapeutics, Inc.",https://www.merck.com/news/merck-to-acquire-caraway-therapeutics-inc/,2023-11-21T00:00:00,management update,
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference,https://www.merck.com/news/merck-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference/,2023-11-20T00:00:00,management update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction/,2023-11-16T00:00:00,regulatory approval,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumabplus-gemcitabine-and-cisplatin-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer/,2023-11-10T00:00:00,regulatory approval,
Merck to Participate in the Jefferies London Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-jefferies-london-healthcare-conference/,2023-11-08T00:00:00,management update,
Merck to Participate in the UBS BioPharma Conference,https://www.merck.com/news/merck-to-participate-in-the-ubs-biopharma-conference/,2023-11-01T00:00:00,management update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-gemcitabine-and-cisplatin-as-treatment-for-patients-with-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer/,2023-11-01T00:00:00,regulatory approval,
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy,https://www.merck.com/news/keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-nephrectomy/,2023-11-01T00:00:00,clinical trial update,
Merck Announces Third-Quarter 2023 Financial Results,https://www.merck.com/news/merck-announces-third-quarter-2023-financial-results/,2023-10-26T00:00:00,financial news,
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer,https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-death-by-more-than-half-versus-chemotherapy-in-patients-with-previously-untreated-locally-advanced-or-metasta/,2023-10-22T00:00:00,clinical trial update,
Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC),https://www.merck.com/news/mercks-welireg-belzutifan-significantly-improved-progression-free-survival-and-objective-response-rates-versus-everolimus-in-certain-previously-treated-patients-with-advanced-renal-ce/,2023-10-21T00:00:00,clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer",https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-concurrent-chemoradiotherapy-significantly-improved-progression-free-survival-pfs-versus-concurrent-chemoradiotherapy-alone-in-newly-diagnosed-hi/,2023-10-20T00:00:00,clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer",https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-statistically-significant-improvement-in-pathological-complete-response-pcr-rate-as-neoadjuvant-therapy-versus-chemotherapy-in/,2023-10-20T00:00:00,clinical trial update,
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-significantly-improved-progression-free-survival-pfs-versus-trastuzumab-and-chemotherapy-in-first-line-her2-positive-advanced-gastric/,2023-10-20T00:00:00,clinical trial update,
"KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)",https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-single-agent-after-surgery-reduced-risk-of-death-by-28-versus-pre-operative-chemotherapy-in-resectable-stage-ii-iiia-o/,2023-10-20T00:00:00,clinical trial update,
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs,https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/,2023-10-19T00:00:00,management update,
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-prevymis-for-prevention-of-cmv-disease-in-high-risk-adult-kidney-transplant-recipients-and-extended-200-day-dosing-in-adult-hsct-recipients-at-risk-fo/,2023-10-17T00:00:00,regulatory approval,
"FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery",https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-resectable-t%e2%89%a54-cm-or-n-nsclc-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-a-single/,2023-10-16T00:00:00,regulatory approval,
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy,https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based/,2023-10-16T00:00:00,regulatory approval,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1),https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-her2-negative-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinom/,2023-10-13T00:00:00,regulatory approval,
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease,https://www.merck.com/news/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease/,2023-10-10T00:00:00,management update,
"Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)",https://www.merck.com/news/merck-announces-pivotal-keynote-671-trial-meets-dual-primary-endpoint-of-overall-survival-os-in-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer-nsclc/,2023-10-10T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery,https://www.merck.com/news/mercks-keytruda-pembrolizumab-met-primary-endpoint-of-disease-free-survival-dfs-in-certain-patients-with-muscle-invasive-urothelial-carcinoma-miuc-after-surgery/,2023-10-05T00:00:00,clinical trial update,
Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26,https://www.merck.com/news/merck-to-hold-third-quarter-2023-sales-and-earnings-conference-call-oct-26/,2023-10-05T00:00:00,management update,
"Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)",https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah/,2023-09-28T00:00:00,regulatory approval,
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer,https://www.merck.com/news/merck-and-eisai-provide-update-on-two-phase-3-trials-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-metastatic-non-small-cell-lung-cancer/,2023-09-22T00:00:00,clinical trial update,
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer,https://www.merck.com/news/merck-announces-phase-3-keynote-a39-ev-302-trial-met-dual-primary-endpoints-of-overall-survival-os-and-progression-free-survival-pfs-in-certain-patients-with-previously-untreated-locally-advanced/,2023-09-22T00:00:00,clinical trial update,
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer,https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-concurrent-chemoradiotherapy-as-treatment-for-patients-with-newly-diagnosed-high-risk-locally-advanced/,2023-09-20T00:00:00,regulatory approval,
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC),https://www.merck.com/news/fda-accepts-for-priority-review-mercks-supplemental-new-drug-application-for-welireg-belzutifan-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma-rcc/,2023-09-19T00:00:00,regulatory approval,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and/,2023-09-15T00:00:00,regulatory approval,
"Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)",https://www.merck.com/news/merck-presents-new-analyses-supporting-the-promising-potential-of-sotatercept-its-investigational-medicine-for-adults-with-pulmonary-arterial-hypertension-pah/,2023-09-11T00:00:00,clinical trial update,
"European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older",https://www.merck.com/news/european-commission-expands-mercks-ervebo-ebola-zaire-vaccine-rvsv%ce%b4g-zebov-gp-live-indication-to-include-children-1-year-of-age-and-older/,2023-09-07T00:00:00,regulatory approval,
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics,https://www.merck.com/news/long-term-follow-up-data-on-sustained-immunogenicity-and-safety-for-gardasil9-published-in-pediatrics/,2023-09-05T00:00:00,clinical trial update,
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-conference/,2023-09-05T00:00:00,management update,
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1),https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcino/,2023-08-29T00:00:00,regulatory approval,
Merck to Participate in the Citi 18th Annual BioPharma Conference,https://www.merck.com/news/merck-to-participate-in-the-citi-18th-annual-biopharma-conference/,2023-08-29T00:00:00,management update,
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616,https://www.merck.com/news/merck-initiates-phase-3-clinical-program-for-oral-pcsk9-inhibitor-candidate-mk-0616/,2023-08-25T00:00:00,clinical trial update,
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-010-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-recurrent-or-metastatic-head-and-ne/,2023-08-25T00:00:00,clinical trial update,
LYNPARZA® (olaparib)Plus Abiraterone and Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/lynparza-olaparibplus-abiraterone-and-prednisone-or-prednisolone-approved-in-japan-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer/,2023-08-24T00:00:00,regulatory approval,
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma,https://www.merck.com/news/merck-announces-welireg-belzutifan-phase-3-litespark-005-trial-met-primary-endpoint-of-progression-free-survival-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma/,2023-08-18T00:00:00,clinical trial update,
"U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older",https://www.merck.com/news/u-s-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older/,2023-08-03T00:00:00,regulatory approval,
Merck Announces Second-Quarter 2023 Financial Results,https://www.merck.com/news/merck-announces-second-quarter-2023-financial-results/,2023-08-01T00:00:00,financial news,
"Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer",https://www.merck.com/news/merck-announces-phase-3-keynote-756-trial-met-primary-endpoint-of-pathological-complete-response-pcr-rate-in-patients-with-high-risk-early-stage-er-her2-breast-cancer/,2023-07-28T00:00:00,clinical trial update,
"Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials",https://www.merck.com/news/merck-announces-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-met-key-immunogenicity-and-safety-endpoints-in-two-phase-3-trials/,2023-07-27T00:00:00,clinical trial update,
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk(Stage IIB-IV) Melanoma,https://www.merck.com/news/merck-and-moderna-initiate-phase-3-study-evaluating-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-resected-high-riskstage-iib-iv-melanom/,2023-07-26T00:00:00,clinical trial update,
Merck Announces Fourth-Quarter 2023 Dividend,https://www.merck.com/news/merck-announces-fourth-quarter-2023-dividend/,2023-07-25T00:00:00,financial news,
Merck Receives Positive European Union CHMP Opinion for Gefapixant,https://www.merck.com/news/merck-receives-positive-european-union-chmp-opinion-for-gefapixant/,2023-07-21T00:00:00,regulatory approval,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1),https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastroesophageal-junction-ge/,2023-07-21T00:00:00,regulatory approval,
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer,https://www.merck.com/news/merck-announces-phase-3-keynote-a18-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/,2023-07-19T00:00:00,clinical trial update,
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1,https://www.merck.com/news/merck-to-hold-second-quarter-2023-sales-and-earnings-conference-call-on-aug-1/,2023-06-29T00:00:00,management update,
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-585-trial-in-locally-advanced-resectable-gastric-and-gastroesophageal-junction-gej-adenocarcinoma/,2023-06-20T00:00:00,clinical trial update,
"Merck Completes Acquisition of Prometheus Biosciences, Inc.",https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/,2023-06-16T00:00:00,management update,
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-met-primary-endpoint-of-progression-free-survival-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesop/,2023-06-16T00:00:00,clinical trial update,
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex),https://www.merck.com/news/u-s-district-court-for-the-district-of-new-jersey-rules-in-favor-of-merck-in-patent-infringement-lawsuit-related-to-bridion-sugammadex/,2023-06-13T00:00:00,management update,
"Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023",https://www.merck.com/news/merck-to-present-data-for-efinopegdutide-mk-6024-an-investigational-glp-1-glucagon-receptor-co-agonist-in-patients-with-nonalcoholic-fatty-liver-disease-nafld-at-easl-2023/,2023-06-12T00:00:00,clinical trial update,
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer,https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-advanced-or-unresectable-biliary-tract-cancer/,2023-06-08T00:00:00,regulatory approval,
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients,https://www.merck.com/news/u-s-fda-approves-new-indication-for-mercks-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-disease-in-high-risk-adult-kidney-transplant-recipients/,2023-06-06T00:00:00,regulatory approval,
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference/,2023-06-06T00:00:00,management update,
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA,https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free/,2023-06-05T00:00:00,clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC",https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-reduced-the-risk-of-event-free-survival-events-by-42-versus-pre-operative/,2023-06-03T00:00:00,clinical trial update,
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma,https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-unresectable-advanced-pleural-mesothelioma/,2023-06-03T00:00:00,clinical trial update,
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC),https://www.merck.com/news/fda-approves-lynparza-olaparibplus-abiraterone-and-prednisone-or-prednisolone-for-treatment-of-adult-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc/,2023-06-01T00:00:00,regulatory approval,
"KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma",https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrates-long-term-durable-survival-benefit-versus-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma/,2023-05-25T00:00:00,clinical trial update,
Merck Announces Third-Quarter 2023 Dividend,https://www.merck.com/news/merck-announces-third-quarter-2023-dividend/,2023-05-23,financial news,
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting,https://www.merck.com/news/merck-to-present-extensive-new-research-demonstrating-significant-progress-in-the-treatment-of-certain-earlier-stage-cancers-and-in-advancing-broad-oncology-pipeline-at-2023-asco-annual-meeting/,2023-05-15,clinical trial update,
Merck to Participate in Bank of America Securities 2023 Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-bank-of-america-securities-2023-healthcare-conference/,2023-05-03,financial news,
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/update-on-fda-advisory-committee-vote-on-lynparza-olaparib-plus-abiraterone-and-prednisone-or-prednisolone-in-first-line-metastatic-castration-resistant-prostate-cancer/,2023-04-28,regulatory approval,
Merck Announces First-Quarter 2023 Financial Results,https://www.merck.com/news/merck-announces-first-quarter-2023-financial-results/,2023-04-27,financial news,
"Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA",https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in/,2023-04-16,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-compared-to-chemotherapy-alone-in-patients-with-advanced-or-unresectable-biliary-tract-cancer/,2023-04-16,clinical trial update,
"Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.",https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/,2023-04-16,management update,
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma,https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junctio/,2023-04-13,regulatory approval,
Merck Named One of Fortune’s 2023 100 Best Companies to Work For®,https://www.merck.com/news/merck-named-one-of-fortunes-2023-100-best-companies-to-work-for/,2023-04-11,management update,
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017),https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-trials-of-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-certain-patients-with-advanced-melanoma-leap-003-and-metastatic-colorectal-cance/,2023-04-07,clinical trial update,
"mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection",https://www.merck.com/news/mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-receives-prime-scheme-designation-from-the-european-medicines-agency-for-adjuva/,2023-04-06,regulatory approval,
Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron’s 100 Most Sustainable U.S. Companies 2023,https://www.merck.com/news/merck-ranked-no-1-in-the-pharmaceutical-industry-among-barrons-100-most-sustainable-us-companies-2023/,2023-04-04,management update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-padcev-enfortumab-vedotin-ejfv-for-first-line-treatment-of-certain-patients-with-locally-advanced-or-metastatic/,2023-04-03,regulatory approval,
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27,https://www.merck.com/news/merck-to-hold-first-quarter-2023-sales-and-earnings-conference-call-on-april-27/,2023-03-30,financial news,
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors,https://www.merck.com/news/fda-converts-to-full-approval-indication-for-keytruda-pembrolizumab-for-certain-adult-and-pediatric-patients-with-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient/,2023-03-29,regulatory approval,
"KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status",https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-progression-free-survival-compared-to-chemotherapy-alone-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma/,2023-03-27,clinical trial update,
"Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)",https://www.merck.com/news/merck-provides-update-from-open-label-arm-of-phase-2-keyvibe-002-trial-evaluating-mk-7684a-a-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small/,2023-03-16,clinical trial update,
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma,https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-malignant-pleural-mesothelioma/,2023-03-10,clinical trial update,
Merck to Present at the Barclays 2023 Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-barclays-2023-global-healthcare-conference/,2023-03-08,financial news,
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy,https://www.merck.com/news/mercks-investigational-activin-signaling-inhibitor-sotatercept-improved-six-minute-walk-distance-by-40-8-meters-at-week-24-versus-placebo-in-adults-with-pulmonary-arterial-hypertension-on-bac/,2023-03-06,clinical trial update,
"Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study",https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/,2023-03-06,clinical trial update,
"US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)",https://www.merck.com/news/us-fda-approves-intramuscular-administration-for-mercks-mmrv-family-of-vaccines-m-m-rii-measles-mumps-and-rubella-virus-vaccine-live-varivax-varicella-virus-vaccine-live-and-proquad/,2023-03-06,regulatory approval,
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/merck-and-astrazeneca-provide-update-on-us-regulatory-review-of-lynparza-olaparib-for-use-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-the-treatment-of-metastatic-castrat/,2023-03-02,regulatory approval,
"Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer",https://www.merck.com/news/merck-announces-phase-3-keynote-671-trial-met-primary-endpoint-of-event-free-survival-efs-in-patients-with-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer/,2023-03-01,clinical trial update,
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789,https://www.merck.com/news/merck-provides-update-on-phase-3-trials-keynote-641-and-keynote-789/,2023-02-28,clinical trial update,
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir),https://www.merck.com/news/merck-and-ridgeback-provide-update-on-eu-marketing-authorization-application-for-lagevrio-molnupiravir/,2023-02-24,regulatory approval,
"Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection",https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-was-granted-breakthrough-therapy-designation-by-the/,2023-02-22,regulatory approval,
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection,https://www.merck.com/news/merck-opens-enrollment-in-new-phase-3-clinical-trials-with-investigational-once-daily-islatravir-in-combination-with-doravirine-for-treatment-of-hiv-1-infection/,2023-02-22,clinical trial update,
"Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline",https://www.merck.com/news/merck-to-present-new-data-for-sotatercept-and-mk-0616-at-acc-23-wcc-demonstrating-significant-progress-in-advancing-its-innovative-cardiovascular-pipeline/,2023-02-21,clinical trial update,
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19,https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/,2023-02-21,clinical trial update,
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk,https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-supplemental-new-drug-application-for-mercks-prevymis-for-prophylaxis-of-cytomegalovirus-disease-in-kidney-transplant-recipients-at-high-risk/,2023-02-17,regulatory approval,
"Merck Announces Sale of Campus in Kenilworth, N.J., to Onyx Equities, LLC",https://www.merck.com/news/merck-announces-sale-of-campus-in-kenilworth-nj-to-onyx-equities-llc/,2023-02-16,management update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction/,2023-02-16,clinical trial update,
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium,https://www.merck.com/news/merck-and-astrazeneca-present-final-results-of-key-secondary-overall-survival-endpoint-from-phase-3-propel-trial-at-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium/,2023-02-16,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma/,2023-02-03,clinical trial update,
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results,https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2022-financial-results/,2023-02-02,financial news,
"FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)",https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-as-adjuvant-treatment-following-surgical-resection-and-platinum-based-chemotherapy-for-patients-with-stage-ib-t2a-%e2%89%a54-centimeters-ii-or-iiia-non/,2023-01-27,regulatory approval,
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility,https://www.merck.com/news/merck-announces-keynote-991-trial-evaluating-keytruda-pembrolizumab-plus-enzalutamide-and-androgen-deprivation-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-to-stop-for/,2023-01-25,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-in-first-line-advanced-or-unresectable-biliary-tract-cancer-in-keynote-966/,2023-01-25,clinical trial update,
Merck Announces Second-Quarter 2023 Dividend,https://www.merck.com/news/merck-announces-second-quarter-2023-dividend/,2023-01-24,financial news,
"Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.",https://www.merck.com/news/merck-completes-tender-offer-to-acquire-imago-biosciences-inc/,2023-01-11,management update,
"Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech",https://www.merck.com/news/merck-named-one-of-americas-most-just-companies-by-just-capital-and-cnbc-industry-leader-in-pharmaceuticals-and-biotech/,2023-01-10,management update,
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2,https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2022-sales-and-earnings-conference-call-february-2/,2023-01-05,financial news,
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/,2023-01-03,financial news,
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference,https://www.merck.com/news/merck-to-present-at-the-goldman-sachs-healthcare-ceos-unscripted-conference/,2022-12-22,financial news,
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer,https://www.merck.com/news/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer/,2022-12-22,management update,
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/,2022-12-21,regulatory approval,
"Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer",https://www.merck.com/news/astellas-seagen-and-merck-announce-fda-acceptance-of-supplemental-biologics-license-applications-for-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-for-the-first-line-trea/,2022-12-20,regulatory approval,
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/astrazeneca-and-merck-provide-update-on-us-regulatory-review-of-lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-as-treatment-of-metastatic-castration-resistant/,2022-12-15,regulatory approval,
"Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial",https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/,2022-12-13,clinical trial update,
"Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.",https://www.merck.com/news/merck-begins-tender-offer-to-acquire-imago-biosciences-inc/,2022-12-12,management update,
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting,https://www.merck.com/news/merck-to-present-data-from-its-hematology-portfolio-and-promising-pipeline-at-the-64th-american-society-of-hematology-ash-annual-meeting/,2022-12-01,clinical trial update,
Merck Announces First-Quarter 2023 Dividend,https://www.merck.com/news/merck-announces-first-quarter-2023-dividend/,2022-11-29,financial news,
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/merck-announces-phase-3-keynote-859-trial-met-primary-endpoint-of-overall-survival-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma/,2022-11-22,clinical trial update,
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference,https://www.merck.com/news/merck-to-present-at-the-5th-annual-evercore-isi-healthconx-conference/,2022-11-21,financial news,
"Merck to Acquire Imago BioSciences, Inc.",https://www.merck.com/news/merck-to-acquire-imago-biosciences-inc/,2022-11-21,management update,
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-receives-positive-opinion-from-eu-chmp-as-treatment-for-certain-patients-with-metastatic-castration-resistant-p/,2022-11-14,regulatory approval,
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck’s GARDASIL® in Systematic Literature Review of 138 Studies,https://www.merck.com/news/reductions-in-certain-types-of-hpv-related-cervical-and-non-cervical-diseases-in-women-and-men-observed-with-real-world-use-of-mercks-gardasil-in-systematic-literature-review-of-138-studies/,2022-11-07,clinical trial update,
Merck Announces Third-Quarter 2022 Financial Results,https://www.merck.com/news/merck-announces-third-quarter-2022-financial-results/,2022-10-27,financial news,
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck,https://www.merck.com/news/robert-m-davis-to-succeed-kenneth-c-frazier-as-chairman-of-merck/,2022-10-26,management update,
"European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents",https://www.merck.com/news/european-commission-expands-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-indication-to-include-infants-children-and-adolescents/,2022-10-24,regulatory approval,
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation,https://www.merck.com/news/mercks-prevymis-demonstrates-efficacy-in-phase-3-study-for-prevention-of-cytomegalovirus-disease-in-adults-after-kidney-transplantation/,2022-10-22,clinical trial update,
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates,https://www.merck.com/news/merck-and-the-bill-melinda-gates-medical-research-institute-announce-licensing-agreement-for-novel-tuberculosis-antibiotic-candidates/,2022-10-18,management update,
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine,https://www.merck.com/news/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine/,2022-10-12,management update,
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines,https://www.merck.com/news/merck-recognized-on-fortunes-2022-change-the-world-list-for-expanding-access-to-hpv-vaccines/,2022-10-10,management update,
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH),https://www.merck.com/news/merck-announces-positive-top-line-results-from-pivotal-phase-3-stellar-trial-evaluating-sotatercept-for-the-treatment-of-adults-with-pulmonary-arterial-hypertension-pah/,2022-10-10,clinical trial update,
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir),https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-new-clinical-and-non-clinical-studies-of-lagevrio-molnupiravir/,2022-10-06,clinical trial update,
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit,https://www.merck.com/news/u-s-court-of-appeals-for-the-federal-circuit-rules-in-favor-of-merck-in-sitagliptin-dihydrogen-phosphate-patent-lawsuit/,2022-09-29,management update,
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27,https://www.merck.com/news/merck-to-hold-third-quarter-2022-sales-and-earnings-conference-call-october-27/,2022-09-29,financial news,
Merck Animal Health Completes Minority Investment in LeeO Precision Farming,https://www.merck.com/news/merck-animal-health-completes-minority-investment-in-leeo-precision-farming/,2022-09-27,management update,
"Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)",https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-four-new-approvals-in-japan-including-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc/,2022-09-27,regulatory approval,
Merck Animal Health to Acquire Vence,https://www.merck.com/news/merck-animal-health-to-acquire-vence/,2022-09-22,management update,
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer,https://www.merck.com/news/lynparza-olaparib-approved-in-china-as-first-line-maintenance-treatment-with-bevacizumab-for-homologous-recombination-deficient-hrd-positive-advanced-ovarian-cancer/,2022-09-22,regulatory approval,
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit,https://www.merck.com/news/u-s-district-court-rules-in-favor-of-merck-in-sitagliptin-phosphate-patent-lawsuit/,2022-09-22,management update,
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection,https://www.merck.com/news/merck-to-initiate-new-phase-3-clinical-program-with-lower-dose-of-daily-oral-islatravir-in-combination-with-doravirine-for-treatment-of-people-with-hiv-1-infection/,2022-09-20,clinical trial update,
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children,https://www.merck.com/news/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-infants-and-children/,2022-09-16,regulatory approval,
"Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) With KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer",https://www.merck.com/news/seagen-astellas-and-merck-announce-results-of-clinical-trial-investigating-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-and-padcev-as-monotherapy-in-first-line-advanced/,2022-09-12,clinical trial update,
Five-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC),https://www.merck.com/news/five-year-data-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-sustained-survival-benefit-versus-chemotherapy-alone-in-two-studies-for-metastatic-non-small-cell-lung-cancer-nsclc/,2022-09-11,clinical trial update,
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma,https://www.merck.com/news/merck-and-eisai-present-results-from-phase-3-leap-002-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-lenvima-monotherapy-in-patients-with-unresectable-hepatocel/,2022-09-10,clinical trial update,
"LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials",https://www.merck.com/news/lynparza-olaparib-in-combination-with-bevacizumab-and-as-monotherapy-demonstrates-clinically-meaningful-long-term-survival-in-certain-patients-with-first-line-advanced-ovarian-cancer-in-expl/,2022-09-09,clinical trial update,
Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care,https://www.merck.com/news/merck-foundation-launches-20-million-initiative-to-advance-equity-in-u-s-cancer-care/,2022-09-08,management update,
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference/,2022-09-06,financial news,
Merck Reports Strong Progress in ESG Focus Areas,https://www.merck.com/news/merck-reports-strong-progress-in-esg-focus-areas/,2022-08-30,management update,
"Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer",https://www.merck.com/news/merck-to-present-new-data-at-esmo-2022-congress-from-its-broad-oncology-portfolio-and-promising-pipeline-demonstrating-commitment-to-improving-long-term-survival-in-multiple-types-of-cancer/,2022-08-29,clinical trial update,
"LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer",https://www.merck.com/news/lynparza-olaparib-approved-in-japan-as-adjuvant-treatment-for-patients-with-brca-mutated-her2-negative-high-recurrent-risk-breast-cancer/,2022-08-25,regulatory approval,
"Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy",https://www.merck.com/news/merck-receives-fast-track-designation-from-the-u-s-fda-for-mk-2060-an-investigational-anticoagulant-therapy/,2022-08-23,regulatory approval,
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review,https://www.merck.com/news/fda-accepts-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-metastatic-castration-resista/,2022-08-16,regulatory approval,
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology,https://www.merck.com/news/merck-and-orna-therapeutics-collaborate-to-advance-ornas-next-generation-of-rna-technology/,2022-08-16,management update,
"LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer",https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer/,2022-08-04,regulatory approval,
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma,https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-002-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-lenvima-monotherapy-in-patients-with-unresectable-hepatocellul/,2022-08-03,clinical trial update,
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-921-trial-evaluating-keytruda-pembrolizumab-plus-chemotherapy-in-patients-with-metastatic-castration-resistant-prostate-cancer/,2022-08-03,clinical trial update,
Merck Announces Second-Quarter 2022 Financial Results,https://www.merck.com/news/merck-announces-second-quarter-2022-financial-results/,2022-07-28,financial news,
Merck Announces Fourth-Quarter 2022 Dividend,https://www.merck.com/news/merck-announces-fourth-quarter-2022-dividend/,2022-07-26,financial news,
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-412-trial-in-unresected-locally-advanced-head-and-neck-squamous-cell-carcinoma/,2022-07-20,clinical trial update,
"Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer",https://www.merck.com/news/merck-and-orion-announce-global-collaboration-for-the-development-and-commercialization-of-odm-208-an-investigational-steroid-synthesis-inhibitor-for-the-treatment-of-metastatic-castration-resistant/,2022-07-13,management update,
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market,https://www.merck.com/news/merck-announces-the-launch-of-the-merck-digital-sciences-studio-to-help-healthcare-startups-quickly-bring-their-innovations-to-market/,2022-06-29,management update,
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28,https://www.merck.com/news/merck-to-hold-second-quarter-2022-sales-and-earnings-conference-call-july-28/,2022-06-29,financial news,
"LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer",https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-as-adjuvant-treatment-for-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer/,2022-06-27,regulatory approval,
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection,https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-adolescent-patients-%e2%89%a512-years-of-age-with-stage-iib-or-iic-melanoma-following-complete-resecti/,2022-06-24,regulatory approval,
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children,https://www.merck.com/news/cdcs-acip-unanimously-votes-to-provisionally-recommend-use-of-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-as-an-option-for-pneumococcal-vaccination-in-infa/,2022-06-22T00:00:00,regulatory approval,
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children,https://www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/,2022-06-22T00:00:00,regulatory approval,
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence,https://www.merck.com/news/results-from-phase-3-propel-trial-of-lynparza-olaparib-plus-abiraterone-in-first-line-metastatic-castration-resistant-prostate-cancer-published-in-nejm-evidence/,2022-06-21T00:00:00,clinical trial update,
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health,https://www.merck.com/news/merck-announces-that-chirfi-guindo-will-lead-marketing-for-merck-human-health/,2022-06-21T00:00:00,management update,
"Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults",https://www.merck.com/news/merck-presents-positive-results-from-phase-1-2-study-evaluating-v116-the-companys-investigational-pneumococcal-conjugate-vaccine-for-adults/,2022-06-21T00:00:00,clinical trial update,
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection,https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-stage-ib-%e2%89%a54-centimeters-iiia-non-small-cell-lung-cancer-following-complete-surgical-resecti/,2022-06-13T00:00:00,regulatory approval,
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-2022-goldman-sachs-43rd-annual-global-healthcare-conference/,2022-06-08T00:00:00,financial news,
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study,https://www.merck.com/news/merck-and-ridgeback-announce-new-data-for-investigational-lagevrio-molnupiravir-from-phase-3-move-out-study/,2022-06-07T00:00:00,clinical trial update,
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline,https://www.merck.com/news/merck-to-hold-investor-event-to-highlight-oncology-portfolio-and-pipeline/,2022-06-07T00:00:00,financial news,
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial,https://www.merck.com/news/adjuvant-treatment-with-mercks-keytruda-pembrolizumab-demonstrates-statistically-significant-clinically-meaningful-improvement-in-distant-metastasis-free-survival-in-patients-with-r/,2022-06-05T00:00:00,clinical trial update,
Merck Announces Third-Quarter 2022 Dividend,https://www.merck.com/news/merck-announces-third-quarter-2022-dividend/,2022-05-24T00:00:00,financial news,
"European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence",https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-triple/,2022-05-24T00:00:00,regulatory approval,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-adolescent-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-c/,2022-05-20T00:00:00,regulatory approval,
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab),https://www.merck.com/news/merck-to-present-data-at-2022-asco-annual-meeting-highlighting-promising-pipeline-medicines-and-significant-progress-in-treating-earlier-stages-of-certain-cancers-with-keytruda-pembrolizumab/,2022-05-10T00:00:00,clinical trial update,
Merck to Participate in Bank of America Securities 2022 Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-bank-of-america-securities-2022-healthcare-conference/,2022-05-04T00:00:00,financial news,
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer,https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-deficient-mismatch-repair-dmmr-tumors-in-five-different-types/,2022-04-29T00:00:00,regulatory approval,
"European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)",https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose/,2022-04-29T00:00:00,regulatory approval,
Merck Announces First-Quarter 2022 Financial Results,https://www.merck.com/news/merck-announces-first-quarter-2022-financial-results/,2022-04-28T00:00:00,financial news,
"Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)",https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-hig/,2022-04-25T00:00:00,regulatory approval,
"Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022",https://www.merck.com/news/merck-announces-that-joseph-romanelli-will-lead-merck-human-health-international-effective-august-1-2022/,2022-04-20T00:00:00,management update,
"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults",https://www.merck.com/news/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ/,2022-04-14T00:00:00,regulatory approval,
Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28,https://www.merck.com/news/merck-to-hold-first-quarter-2022-sales-and-earnings-conference-call-april-28/,2022-04-08T00:00:00,financial news,
Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need,https://www.merck.com/news/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need/,2022-04-05T00:00:00,financial news,
"Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access",https://www.merck.com/news/expansion-of-elkton-virginia-manufacturing-facility-to-further-increase-mercks-hpv-vaccine-supply-and-support-broader-and-equitable-access/,2022-04-04T00:00:00,commercialized drug update,
Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children,https://www.merck.com/news/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children/,2022-04-01T00:00:00,regulatory approval,
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo,https://www.merck.com/news/merck-and-ridgeback-to-present-data-demonstrating-that-treatment-with-lagevrio-molnupiravir-was-associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo/,2022-04-01T00:00:00,clinical trial update,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-tumors-in-five-different-types/,2022-03-25T00:00:00,regulatory approval,
"Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)",https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-c/,2022-03-25T00:00:00,regulatory approval,
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer,https://www.merck.com/news/merck-announces-retirement-of-dr-roy-d-baynes-dr-eliav-barr-appointed-head-of-global-clinical-development-and-chief-medical-officer/,2022-03-23T00:00:00,management update,
Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT,https://www.merck.com/news/systematic-review-and-meta-analysis-of-real-world-observational-studies-provide-additional-evidence-of-effectiveness-of-prevymis-in-preventing-cytomegalovirus-infection-and-disease-in-adults/,2022-03-22T00:00:00,clinical trial update,
"FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation",https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-msi%e2%80%91h-dmmr-advanced-endometrial-carcinoma-who-have-disease-progression-following-prior-systemic-therapy-in-any-se/,2022-03-21T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression,https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-disease-free-survival-dfs-versus-placebo-as-adjuvant-therapy-in-patients-with-stage-ib-iiia-non-small-cell-lung-cancer-nsclc-r/,2022-03-17T00:00:00,clinical trial update,
"LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial",https://www.merck.com/news/lynparza-olaparib-reduced-risk-of-death-by-32-in-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer-in-phase-3-olympia-trial/,2022-03-16T00:00:00,clinical trial update,
Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility,https://www.merck.com/news/merck-announces-keylynk-010-trial-evaluating-keytruda-pembrolizumab-in-combination-with-lynparza-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-to-stop-for-f/,2022-03-15T00:00:00,clinical trial update,
"FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy",https://www.merck.com/news/fda-approves-lynparza-olaparib-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-gbrcam-her2-negative-high-risk-early-breast-cancer-who-have-been-treated-with-neoadjuvant-or-adj/,2022-03-11T00:00:00,regulatory approval,
Merck to Hold Investor Event to Highlight Growing Cardiovascular Portfolio and Pipeline,https://www.merck.com/news/merck-to-hold-investor-event-to-highlight-growing-cardiovascular-portfolio-and-pipeline/,2022-03-07T00:00:00,financial news,
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial,https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-significant-improvement-in-distant-metastasis-free-survival-dmfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-resected-stage/,2022-03-07T00:00:00,clinical trial update,
Merck to Participate in Cowen’s 42nd Annual Health Care Conference,https://www.merck.com/news/merck-to-participate-in-cowens-42nd-annual-health-care-conference/,2022-03-04T00:00:00,financial news,
Dr. Julie L. Gerberding to Retire from Merck,https://www.merck.com/news/dr-julie-l-gerberding-to-retire-from-merck/,2022-03-01T00:00:00,management update,
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma,https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-approved-in-japan-for-radically-unresectable-or-metastatic-renal-cell-carcinoma/,2022-02-25T00:00:00,regulatory approval,
"Merck Shares Environmental, Social & Governance Priorities and Strategy",https://www.merck.com/news/merck-shares-environmental-social-governance-priorities-and-strategy/,2022-02-23T00:00:00,management update,
Merck Announces New Leadership for Human Health Business,https://www.merck.com/news/merck-announces-new-leadership-for-human-health-business/,2022-02-16T00:00:00,management update,
"LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status",https://www.merck.com/news/lynparza-olaparib-plus-abiraterone-reduced-risk-of-disease-progression-or-death-by-34-versus-abiraterone-in-first-line-metastatic-castration-resistant-prostate-cancer-regardless-of-biomarker/,2022-02-14T00:00:00,clinical trial update,
"Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities",https://www.merck.com/news/merck-to-hold-event-to-discuss-long-term-environmental-social-governance-priorities/,2022-02-14T00:00:00,financial news,
Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference,https://www.merck.com/news/merck-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference/,2022-02-10T00:00:00,financial news,
Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine,https://www.merck.com/news/pivotal-phase-3-data-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc-published-in-the-new-england-journal-of-medicine/,2022-02-09T00:00:00,clinical trial update,
"Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States",https://www.merck.com/news/merck-and-ridgeback-announce-that-3-1-million-courses-of-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-have-been-supplied-to-the-u-s-government-for-use-in-the-united-states/,2022-02-08T00:00:00,commercialized drug update,
Merck to Participate in the Guggenheim Oncology Conference 2022,https://www.merck.com/news/merck-to-participate-in-the-guggenheim-oncology-conference-2022/,2022-02-04T00:00:00,financial news,
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results,https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2021-financial-results/,2022-02-03T00:00:00,financial news,
"Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies",https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-demonstrated-activity-against-omicron-variant-in-in-vitro-studies/,2022-01-28T00:00:00,clinical trial update,
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery,https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery/,2022-01-27T00:00:00,regulatory approval,
Merck Announces Second-Quarter 2022 Dividend,https://www.merck.com/news/merck-announces-second-quarter-2022-dividend/,2022-01-25T00:00:00,financial news,
Merck Provides U.S. and Japan Regulatory Update for Gefapixant,https://www.merck.com/news/merck-provides-u-s-and-japan-regulatory-update-for-gefapixant/,2022-01-24T00:00:00,regulatory approval,
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine,https://www.merck.com/news/results-from-pivotal-phase-3-keynote-775-study-309-trial-of-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-advanced-endometrial-carcinoma-published-in-the-new-england-journal-of-med/,2022-01-20T00:00:00,clinical trial update,
Frank Clyburn to Leave Merck,https://www.merck.com/news/frank-clyburn-to-leave-merck/,2022-01-20T00:00:00,management update,
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib,https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-in-certain-patients-with-advanced-hepatocellular-carcinoma-hcc-previously-treated-with-sora/,2022-01-18T00:00:00,clinical trial update,
"Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine",https://www.merck.com/news/merck-and-ridgeback-announce-supply-agreement-with-unicef-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine/,2022-01-18T00:00:00,commercialized drug update,
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression,https://www.merck.com/news/mercks-keytruda-pembrolizumab-showed-statistically-significant-improvement-in-disease-free-survival-versus-placebo-as-adjuvant-treatment-for-patients-with-stage-ib-iiia-non-small-cell/,2022-01-10T00:00:00,clinical trial update,
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3,https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2021-sales-and-earnings-conference-call-on-february-3/,2022-01-07T00:00:00,financial news,
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/,2022-01-04T00:00:00,financial news,
"KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy",https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-approved-in-japan-for-patients-with-unresectable-advanced-or-recurrent-endometrial-carcinoma-that-progressed-after-cancer-chemotherapy/,2021-12-27T00:00:00,regulatory approval,
"Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan",https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-receives-special-approval-for-emergency-in-japan/,2021-12-24T00:00:00,regulatory approval,
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19,https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-receives-u-s-fda-emergency-use-authorization-for-the-treatmentof-high-risk-adults-with-mild-to-moderate-covid-19/,2021-12-23T00:00:00,regulatory approval,
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir,https://www.merck.com/news/merck-and-ridgeback-announce-u-k-government-to-purchase-additional-1-75-million-courses-of-molnupiravir/,2021-12-22T00:00:00,commercialized drug update,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-following-surgery/,2021-12-17T00:00:00,regulatory approval,
"Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine",https://www.merck.com/news/merck-and-ridgeback-announce-publication-of-phase-3-study-of-molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-in-the-new-england-journal-of-medicine/,2021-12-16T00:00:00,clinical trial update,
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older,https://www.merck.com/news/european-commission-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-individuals-18-years-of-age-and-older/,2021-12-15T00:00:00,regulatory approval,
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection,https://www.merck.com/news/merck-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection/,2021-12-13T00:00:00,clinical trial update,
Merck Issues $1 Billion Inaugural Sustainability Bond,https://www.merck.com/news/merck-issues-1-billion-inaugural-sustainability-bond/,2021-12-13T00:00:00,financial news,
Merck Prices $8.0 Billion Debt Offering,https://www.merck.com/news/merck-prices-8-0-billion-debt-offering-2/,2021-12-07T00:00:00,financial news,
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities,https://www.merck.com/news/merck-announces-additional-150m-investment-through-2025-to-help-end-maternal-mortality-inequities/,2021-12-07T00:00:00,financial news,
"Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection",https://www.merck.com/news/merck-announces-pause-in-enrollment-for-two-phase-3-clinical-trials-of-investigational-once-monthly-oral-islatravir-for-pre-exposure-prophylaxis-prep-of-hiv-1-infection/,2021-12-06T00:00:00,clinical trial update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/,2021-12-03T00:00:00,regulatory approval,
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children,https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children/,2021-12-01T00:00:00,regulatory approval,
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults,https://www.merck.com/news/merck-and-ridgeback-statement-on-positive-fda-advisory-committee-vote-for-investigational-oral-antiviral-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-in-high-risk-adults/,2021-11-30T00:00:00,regulatory approval,
Merck Announces First-Quarter 2022 Dividend,https://www.merck.com/news/merck-announces-first-quarter-2022-dividend/,2021-11-30T00:00:00,financial news,
"Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma",https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-radically-unresectable-advanced-or-recurrent-esophageal-car/,2021-11-30T00:00:00,regulatory approval,
"FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review",https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-as-adjuvant-treatment-in-brca-mutated-her2-negative-high-risk-early-breast-cancer-and-grants-prior/,2021-11-30T00:00:00,regulatory approval,
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma,https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-patients-with-certain-types-of-endometrial-carcinoma/,2021-11-29T00:00:00,regulatory approval,
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma,https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-adult-patients-with-advanced-renal-cell-carcinoma/,2021-11-29T00:00:00,regulatory approval,
"Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19",https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/,2021-11-26T00:00:00,clinical trial update,
Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference,https://www.merck.com/news/merck-to-present-at-the-4th-annual-evercore-isi-healthconx-conference/,2021-11-24T00:00:00,financial news,
Merck Completes Acquisition of Acceleron Pharma Inc.,https://www.merck.com/news/merck-completes-acquisition-of-acceleron-pharma-inc/,2021-11-22T00:00:00,management update,
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.,https://www.merck.com/news/merck-completes-tender-offer-to-acquire-acceleron-pharma-inc/,2021-11-19T00:00:00,management update,
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1,https://www.merck.com/news/merck-provides-update-on-phase-2-clinical-trial-of-once-weekly-investigational-combination-of-mk-8507-and-islatravir-for-the-treatment-of-people-living-with-hiv-1/,2021-11-18T00:00:00,clinical trial update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery/,2021-11-18T00:00:00,regulatory approval,
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.,https://www.merck.com/news/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-and-extension-of-tender-offer-to-acquire-acceleron-pharma-inc/,2021-11-17T00:00:00,management update,
"Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting",https://www.merck.com/news/merck-and-ridgeback-to-present-phase-3-data-for-molnupiravir-an-investigational-oral-covid-19-antiviral-medicine-at-american-society-of-tropical-medicine-and-hygiene-astmh-2021-annual-meeting/,2021-11-17T00:00:00,clinical trial update,
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event,https://www.merck.com/news/merck-announces-initiation-of-phase-3-study-evaluating-verquvo-vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-who-have-not-had-a-recent-worsening-heart-failure/,2021-11-11T00:00:00,clinical trial update,
"Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval",https://www.merck.com/news/merck-and-ridgeback-announce-japanese-government-to-purchase-1-6-million-courses-of-molnupiravir-an-investigational-oral-covid-19-antiviral-medicine-upon-authorization-or-approval/,2021-11-10T00:00:00,commercialized drug update,
"Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults",https://www.merck.com/news/merck-and-ridgeback-announce-u-s-government-to-purchase-1-4-million-additional-courses-of-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-a/,2021-11-09T00:00:00,commercialized drug update,
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.,https://www.merck.com/news/merck-announces-receipt-of-antitrust-clearance-in-germany-and-austria-relating-to-tender-offer-to-acquire-acceleron-pharma-inc/,2021-11-08T00:00:00,management update,
"Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World",https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-covid-19-antiviral-medicine-receives-first-authorization-in-the-world/,2021-11-04T00:00:00,regulatory approval,
New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease,https://www.merck.com/news/new-research-for-keytruda-pembrolizumab-at-society-for-melanoma-research-smr-2021-congress-reinforces-mercks-commitment-to-patients-with-melanoma-across-stages-of-disease/,2021-10-31T00:00:00,clinical trial update,
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.,https://www.merck.com/news/merck-announces-withdrawal-and-refiling-under-the-hart-scott-rodino-act-and-extension-of-tender-offer-to-acquire-acceleron-pharma-inc/,2021-10-29T00:00:00,management update,
Merck Announces Third-Quarter 2021 Financial Results,https://www.merck.com/news/merck-announces-third-quarter-2021-financial-results/,2021-10-28T00:00:00,financial news,
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021,https://www.merck.com/news/merck-presents-new-data-from-ongoing-phase-2b-clinical-trial-evaluating-efficacy-and-safety-of-investigational-islatravir-in-combination-with-doravirine-through-144-weeks-for-hiv-1-treatment-at-eacs-2/,2021-10-27T00:00:00,clinical trial update,
"The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries",https://www.merck.com/news/the-medicines-patent-pool-mpp-and-merck-enter-into-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low-and-middle-income-countri/,2021-10-27T00:00:00,commercialized drug update,
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults,https://www.merck.com/news/gilead-and-merck-initiate-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-lenacapavir-and-investigational-islatravir-for-hiv-1-treatment-in-virologically-suppressed-adul/,2021-10-26T00:00:00,clinical trial update,
"Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection",https://www.merck.com/news/merck-announces-positive-top-line-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-oral-fixed-dose-combination-of-doravirine-islatravir-for-the-treatment-of-people-with-hiv-1/,2021-10-25T00:00:00,clinical trial update,
"Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults",https://www.merck.com/news/merck-and-ridgeback-announce-initiation-of-a-rolling-review-by-the-european-medicines-agency-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-covid-19-in-adults/,2021-10-25T00:00:00,regulatory approval,
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC),https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast/,2021-10-22T00:00:00,regulatory approval,
CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults,https://www.merck.com/news/cdc-acip-unanimously-votes-to-provisionally-recommend-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-series-with-pneumovax-23-pneumococcal-vaccine-polyvalen/,2021-10-20T00:00:00,regulatory approval,
"Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles",https://www.merck.com/news/merck-issues-voluntary-nationwide-recall-of-cubicin-daptomycin-for-injection-500-mg-lot-934778-due-to-presence-of-particulate-matter-identified-as-glass-particles/,2021-10-19T00:00:00,commercialized drug update,
Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer,https://www.merck.com/news/merck-and-eisai-receive-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-two-different-types-of-cancer/,2021-10-15T00:00:00,regulatory approval,
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older,https://www.merck.com/news/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older/,2021-10-15T00:00:00,regulatory approval,
"FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)",https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose-tum/,2021-10-13T00:00:00,regulatory approval,
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.,https://www.merck.com/news/merck-begins-tender-offer-to-acquire-acceleron-pharma-inc/,2021-10-12T00:00:00,management update,
"Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults",https://www.merck.com/news/merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-u-s-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-c/,2021-10-11T00:00:00,regulatory approval,
"Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer",https://www.merck.com/news/merck-and-emmy-nominated-actress-yvonne-orji-unveil-uncovering-tnbc-highlighting-the-challenges-faced-by-black-women-diagnosed-with-triple-negative-breast-cancer/,2021-10-05T00:00:00,clinical trial update,
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study,https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/,2021-10-01T00:00:00,clinical trial update,
Merck to Acquire Acceleron Pharma Inc.,https://www.merck.com/news/merck-to-acquire-acceleron-pharma-inc/,2021-09-30T00:00:00,management update,
Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director,https://www.merck.com/news/merck-announces-appointment-of-thomas-h-glocer-as-independent-lead-director/,2021-09-29T00:00:00,management update,
Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28,https://www.merck.com/news/merck-to-hold-third-quarter-2021-sales-and-earnings-conference-call-on-october-28/,2021-09-28T00:00:00,financial news,
Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib,https://www.merck.com/news/merck-announces-keytruda-pembrolizumab-met-primary-endpoint-of-overall-survival-os-in-patients-with-advanced-hepatocellular-carcinoma-previously-treated-with-sorafenib/,2021-09-27T00:00:00,clinical trial update,
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC),https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-significantly-delayed-disease-progression-in-patients-regardless-of-biomarker-status-in-propel-phase-3-trial-in-first-line-metastatic-castrati/,2021-09-24T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10),https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-whos/,2021-09-19T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting,https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-rfs-in-patients-with-resected-high-risk-stage-ii-melanoma-compared-to-placebo-in-the-adjuvant-setting/,2021-09-18T00:00:00,clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer",https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-reduced-risk-of-death-by-one-third-versus-chemotherapy-with-or-without-bevacizumab-as-first-line-treatment/,2021-09-18T00:00:00,clinical trial update,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10),https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breas/,2021-09-17T00:00:00,regulatory approval,
"Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer",https://www.merck.com/news/merck-to-present-new-data-from-its-broad-oncology-portfolio-and-pipeline-at-esmo-2021-including-in-earlier-stages-of-cancer/,2021-09-08T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma,https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-locally-advanced-unresectable-or-metastatic-esophageal-or-ga/,2021-09-07T00:00:00,regulatory approval,
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-19th-annual-healthcare-conference/,2021-09-07T00:00:00,financial news,
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection,https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-3-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection/,2021-09-01T00:00:00,clinical trial update,
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer),https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/,2021-08-31T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan,https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan-2/,2021-08-26T00:00:00,regulatory approval,
"Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)",https://www.merck.com/news/merck-announces-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-met-key-immunogenicity-and-safety-endpoints-in-phase-3-pivotal-trial-evaluating-use-in-infants-pneu-ped-v114-029/,2021-08-25T00:00:00,clinical trial update,
Leslie A. Brun Resigns from Merck Board of Directors,https://www.merck.com/news/leslie-a-brun-resigns-from-merck-board-of-directors/,2021-08-20T00:00:00,management update,
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors,https://www.merck.com/news/fda-approves-mercks-hypoxia-inducible-factor-2-alpha-hif-2%ce%b1-inhibitor-welireg-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease/,2021-08-13T00:00:00,regulatory approval,
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC),https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-for-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma-rcc/,2021-08-11T00:00:00,regulatory approval,
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma,https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-as-single-agent-for-certain-patients-with-msi-h-dmmr-advanced-endometrial-carcinoma/,2021-08-10T00:00:00,regulatory approval,
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery,https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-as-adjuvant-therapy-in-certain-patients-with-renal-cell-carcinoma-rcc-foll/,2021-08-10T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial,https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-prolonged-recurrence-free-survival-rfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-stage-ii-resected-high-risk-melanoma-in/,2021-08-05T00:00:00,clinical trial update,
Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer,https://www.merck.com/news/merck-announces-appointment-of-cristal-n-downing-as-chief-communications-public-affairs-officer/,2021-07-29T00:00:00,management update,
Merck Announces Second-Quarter 2021 Financial Results,https://www.merck.com/news/merck-announces-second-quarter-2021-financial-results/,2021-07-29T00:00:00,financial news,
Merck Announces Fourth-Quarter 2021 Dividend,https://www.merck.com/news/merck-announces-fourth-quarter-2021-dividend/,2021-07-27T00:00:00,financial news,
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10),https://www.merck.com/news/merck-announces-phase-3-keynote-355-trial-met-primary-endpoint-of-overall-survival-os-in-patients-with-metastatic-triple-negative-breast-cancer-whose-tumors-expressed-pd-l1-cps-%e2%89%a510/,2021-07-27T00:00:00,clinical trial update,
"FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery",https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued/,2021-07-27T00:00:00,regulatory approval,
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma,https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-for-patients-with-certain-types-of-advanced-endometrial-carcinoma/,2021-07-22T00:00:00,regulatory approval,
VERQUVO® (vericiguat) Approved in the European Union,https://www.merck.com/news/verquvo-vericiguat-approved-in-the-european-union/,2021-07-21T00:00:00,regulatory approval,
"Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021",https://www.merck.com/news/merck-presents-new-data-from-ongoing-phase-2a-clinical-trial-evaluating-the-safety-tolerability-and-pharmacokinetics-of-investigational-once-monthly-oral-islatravir-for-hiv-1-prevention-at-ias-2021/,2021-07-20T00:00:00,clinical trial update,
Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes,https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/,2021-07-16T00:00:00,regulatory approval,
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC,https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-showed-statistically-significant-event-free-survival-efs-result-versus-neoadjuvant-chemo/,2021-07-15T00:00:00,clinical trial update,
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021,https://www.merck.com/news/merck-announces-presentation-of-new-data-from-broad-hiv-program-at-ias-2021/,2021-07-12T00:00:00,clinical trial update,
"Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)",https://www.merck.com/news/interim-results-from-phase-2-3-studies-of-molnupiravir-an-investigational-oral-antiviral-therapeutic-for-mild-to-moderate-covid-19-presented-at-the-european-congress-of-clinical-microbiology-i/,2021-07-12T00:00:00,clinical trial update,
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC),https://www.merck.com/news/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-locally-advanced-cutaneous-squamous-cell-carcinoma-cscc/,2021-07-06T00:00:00,regulatory approval,
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US,https://www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-in-third-line-gastric-cancer-in-the-us/,2021-07-01T00:00:00,clinical trial update,
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29,https://www.merck.com/news/merck-to-hold-second-quarter-2021-sales-and-earnings-conference-call-on-july-29/,2021-06-30T00:00:00,financial news,
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-for-certain-patients-with-esophageal-cancer-or-her2-negative-gastroesophageal-junction-gej-adenocarcinom/,2021-06-29T00:00:00,regulatory approval,
Merck Appoints Michael Klobuchar Chief Strategy Officer,https://www.merck.com/news/merck-appoints-michael-klobuchar-chief-strategy-officer/,2021-06-24T00:00:00,management update,
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/lynparza-olaparib-approved-in-china-for-the-treatment-of-certain-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/,2021-06-24T00:00:00,regulatory approval,
"Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer",https://www.merck.com/news/merck-announces-phase-3-keynote-826-trial-met-dual-primary-endpoints-of-overall-survival-os-and-progression-free-survival-pfs-in-patients-with-persistent-recurrent-or-metastatic-cervical-cancer/,2021-06-22T00:00:00,clinical trial update,
Merck to Participate in the Guggenheim Biopharma Strategy Series,https://www.merck.com/news/merck-to-participate-in-the-guggenheim-biopharma-strategy-series/,2021-06-17T00:00:00,financial news,
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All,https://www.merck.com/news/merck-announces-the-kenneth-c-frazier-award-for-maternal-health-equity-to-accelerate-progress-towards-improved-birth-outcomes-for-all/,2021-06-16T00:00:00,management update,
"Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19",https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19/,2021-06-09T00:00:00,clinical trial update,
MSD Animal Health to Acquire Assets of LIC Automation Ltd.,https://www.merck.com/news/msd-animal-health-to-acquire-assets-of-lic-automation-ltd/,2021-06-07T00:00:00,management update,
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting,https://www.merck.com/news/new-data-on-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-sunitinib-in-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-from-pivotal-phase-3-clear-keynote-5/,2021-06-07T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC),https://www.merck.com/news/mercks-keytruda-pembrolizumab-given-after-surgery-reduced-the-risk-of-disease-recurrence-or-death-by-32-versus-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc/,2021-06-03T00:00:00,clinical trial update,
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial,https://www.merck.com/news/lynparza-olaparib-reduced-the-risk-of-invasive-disease-recurrence-or-death-by-42-versus-placebo-in-adjuvant-treatment-of-patients-with-germline-brca-mutations-and-high-risk-her2-negative-early/,2021-06-03T00:00:00,clinical trial update,
Merck Announces Completion of Organon & Co. Spinoff,https://www.merck.com/news/merck-announces-completion-of-organon-co-spinoff/,2021-06-03T00:00:00,management update,
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States,https://www.merck.com/news/merck-and-sanofis-first-and-only-six-in-one-pediatric-combination-vaccine-now-available-in-the-united-states/,2021-06-01T00:00:00,commercialized drug update,
Merck Announces Third-Quarter 2021 Dividend,https://www.merck.com/news/merck-announces-third-quarter-2021-dividend/,2021-05-25T00:00:00,financial news,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-first-line-treatment-for-certain-patients-with-esophageal-cancer-or-her2-negative-gastroe/,2021-05-24T00:00:00,regulatory approval,
"Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine",https://www.merck.com/news/merck-announces-positive-topline-results-from-pneu-direction-v114-027-and-pneu-plan-v114-024-phase-3-pediatric-studies-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-va/,2021-05-20T00:00:00,clinical trial update,
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC),https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer-tnbc/,2021-05-13T00:00:00,clinical trial update,
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff,https://www.merck.com/news/merck-declares-record-date-and-dividend-for-the-organon-co-spinoff/,2021-05-07T00:00:00,financial news,
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program,https://www.merck.com/news/merck-highlights-scientific-data-at-2021-asco-annual-meeting-across-more-than-20-cancer-types-from-broad-oncology-research-program/,2021-05-06T00:00:00,clinical trial update,
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma,https://www.merck.com/news/merck-and-eisai-receive-priority-review-from-fda-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-applications-for-advanced-renal-cell-carcinoma-and-for-advanced-endometrial-carcinom/,2021-05-06T00:00:00,regulatory approval,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-combined-with-trastuzumab-and-chemotherapy-as-first-line-treatment-in-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-g/,2021-05-05T00:00:00,regulatory approval,
"Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth",https://www.merck.com/news/merck-hosts-organon-investor-day-outlining-new-companys-vision-focus-and-business-model-for-sustained-growth/,2021-05-03T00:00:00,financial news,
"Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19",https://www.merck.com/news/amid-humanitarian-crisis-in-india-merck-announces-voluntary-licensing-agreements-with-five-indian-generics-manufacturers-to-accelerate-and-expand-global-access-to-molnupiravir-an-investigational-ora/,2021-04-27T00:00:00,clinical trial update,
Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025,https://www.merck.com/news/merck-accelerates-climate-goals-announces-carbon-neutrality-in-operations-by-2025/,2021-04-26T00:00:00,management update,
Merck to Discontinue Development of MK-7110 for COVID-19,https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/,2021-04-15T00:00:00,clinical trial update,
"Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19",https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/,2021-04-15T00:00:00,clinical trial update,
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week,https://www.merck.com/news/merck-expands-safer-childbirth-cities-initiative-to-20th-community-led-project-advancing-maternal-health-equity-during-black-maternal-health-week/,2021-04-14T00:00:00,management update,
Organon Announces Pricing of Senior Notes Offering,https://www.merck.com/news/organon-announces-pricing-of-senior-notes-offering/,2021-04-08T00:00:00,financial news,
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery,https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-disease-free-survival-dfs-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc-following-surgery/,2021-04-08T00:00:00,clinical trial update,
Organon Announces Proposed Senior Notes Offering,https://www.merck.com/news/organon-announces-proposed-senior-notes-offering/,2021-04-06T00:00:00,financial news,
Merck Completes Acquisition of Pandion Therapeutics,https://www.merck.com/news/merck-completes-acquisition-of-pandion-therapeutics/,2021-04-01T00:00:00,management update,
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon,https://www.merck.com/news/merck-announces-acquisition-of-alydia-health-on-behalf-of-its-planned-spinoff-of-organon/,2021-03-30T00:00:00,management update,
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-updated-label-of-keytruda-pembrolizumab-to-include-results-of-phase-3-keynote-361-trial-in-certain-adult-patients-with-locally-advanced-or-metastati/,2021-03-30T00:00:00,regulatory approval,
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC),https://www.merck.com/news/merck-receives-complete-response-letter-from-us-fda-for-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer-tnb/,2021-03-29T00:00:00,regulatory approval,
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29,https://www.merck.com/news/merck-to-hold-first-quarter-2021-sales-and-earnings-conference-call-on-april-29/,2021-03-29T00:00:00,financial news,
Merck Appoints Caroline Litchfield Chief Financial Officer,https://www.merck.com/news/merck-appoints-caroline-litchfield-chief-financial-officer/,2021-03-24T00:00:00,management update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-platinum-and-fluoropyrimidine-based-chemotherapy-for-treatment-of-certain-patients-with-locally-advanced-or-metastatic-esophageal-or-g/,2021-03-23T00:00:00,regulatory approval,
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study,https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-significantly-improved-progression-free-survival-and-overall-survival-versus-chemotherapy-in-patients-with-advanced-endometrial-cancer-fo/,2021-03-19T00:00:00,clinical trial update,
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.,https://www.merck.com/news/merck-announces-filing-of-form-10-registration-statement-in-connection-with-planned-spinoff-of-organon-co/,2021-03-17T00:00:00,management update,
European Commission Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL),https://www.merck.com/news/european-commission-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-adult-and-pediatric-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl/,2021-03-17T00:00:00,regulatory approval,
Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health,https://www.merck.com/news/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health/,2021-03-17T00:00:00,management update,
Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482),https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-drug-application-for-hif-2%ce%b1-inhibitor-belzutifan-mk-6482/,2021-03-16T00:00:00,regulatory approval,
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead,https://www.merck.com/news/merck-to-host-investor-briefing-to-discuss-broad-hiv-development-program-and-newly-announced-collaboration-with-gilead/,2021-03-15T00:00:00,financial news,
"Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV",https://www.merck.com/news/gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-long-acting-investigational-treatment-combinations-of-lenacapavir-and-islatravir-in-hiv-2/,2021-03-15T00:00:00,clinical trial update,
Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021,https://www.merck.com/news/merck-presents-results-from-phase-1-trial-evaluating-investigational-islatravir-subdermal-implant-for-the-prevention-of-hiv-1-infection-at-croi-2021/,2021-03-08T00:00:00,clinical trial update,
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir,https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/,2021-03-06T00:00:00,clinical trial update,
Merck Begins Tender Offer to Acquire Pandion Therapeutics,https://www.merck.com/news/merck-begins-tender-offer-to-acquire-pandion-therapeutics/,2021-03-04T00:00:00,management update,
Merck to Present at the Barclays Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-barclays-global-healthcare-conference-2/,2021-03-03T00:00:00,financial news,
Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021,https://www.merck.com/news/merck-to-present-new-data-from-various-hiv-research-and-development-programs-at-croi-2021/,2021-03-03T00:00:00,clinical trial update,
Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck’s Manufacturing Capacity for COVID-19 Vaccines and Medicines,https://www.merck.com/news/merck-to-help-produce-johnson-barda-to-provide-merck-with-funding-to-expand-mercks-manufacturing-capacity-for-covid-19-vaccines-and-medicines/,2021-03-02T00:00:00,management update,
Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide,https://www.merck.com/news/merck-announces-fifth-round-of-global-grants-to-tackle-maternal-mortality-and-promote-health-equity-worldwide/,2021-03-02,Corporate Responsibility News,
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US,https://www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-in-metastatic-small-cell-lung-cancer-in-the-us/,2021-03-01,clinical trial update,
U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review,https://www.merck.com/news/u-s-fda-accepts-mercks-gefapixant-new-drug-application-for-review/,2021-03-01,regulatory approval,
Merck Animal Health Completes Acquisition of Poultry Sense Limited,https://www.merck.com/news/merck-animal-health-completes-acquisition-of-poultry-sense-limited/,2021-02-25,management update,
Merck to Acquire Pandion Therapeutics,https://www.merck.com/news/merck-to-acquire-pandion-therapeutics/,2021-02-25,management update,
Merck to Present at the Cowen 41st Annual Health Care Conference,https://www.merck.com/news/merck-to-present-at-the-cowen-41st-annual-health-care-conference/,2021-02-24,financial news,
Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis,https://www.merck.com/news/independent-data-monitoring-committee-concludes-olympia-trial-of-lynparza-olaparib-crossed-superiority-boundary-for-invasive-disease-free-survival-vs-placebo-at-planned-interim-analysis/,2021-02-17,clinical trial update,
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma,https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrated-superior-progression-free-survival-pfs-and-overall-survival-os-versus-sunitinib-as-first-line-treatment-for-patients-wit/,2021-02-13,clinical trial update,
Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results,https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2020-financial-results/,2021-02-04,financial news,
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman,https://www.merck.com/news/kenneth-c-frazier-to-retire-as-merck-ceo-board-elects-robert-m-davis-as-successor-frazier-to-continue-as-executive-chairman/,2021-02-04,management update,
Dr. Stephen Mayo Elected to Merck Board of Directors,https://www.merck.com/news/dr-stephen-mayo-elected-to-merck-board-of-directors/,2021-02-01,management update,
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-expanded-approval-of-keytruda-pembrolizumab-in-certain-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/,2021-02-01,regulatory approval,
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer,https://www.merck.com/news/merck-presents-results-from-head-to-head-phase-3-keynote-598-trial-evaluating-keytruda-pembrolizumab-in-combination-with-ipilimumab-versus-keytruda-monotherapy-in-certain-patients-with-metasta/,2021-01-29,clinical trial update,
Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US,https://www.merck.com/news/merck-announces-second-cohort-of-safer-childbirth-cities-organizations-committed-to-improving-maternal-health-equity-and-reducing-preventable-maternal-deaths-in-the-us/,2021-01-27,Corporate Responsibility News,
Merck Announces Second-Quarter 2021 Dividend,https://www.merck.com/news/merck-announces-second-quarter-2021-dividend-2/,2021-01-26,financial news,
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021,https://www.merck.com/news/merck-presents-interim-findings-from-phase-2a-clinical-trial-evaluating-investigational-once-monthly-oral-islatravir-for-the-prevention-of-hiv-1-infection-at-hivr4p-2021/,2021-01-26,clinical trial update,
European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer,https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colore/,2021-01-26,regulatory approval,
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates,https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/,2021-01-25,clinical trial update,
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat),https://www.merck.com/news/merck-announces-u-s-fda-approval-of-verquvo-vericiguat/,2021-01-20,regulatory approval,
"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older",https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older/,2021-01-12,regulatory approval,
Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4,https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2020-sales-and-earnings-conference-call-on-february-4/,2021-01-08,financial news,
Merck to Present at the 39th Annual J.P. Morgan Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/,2021-01-04,financial news,
LYNPARZA® (olaparib) Receives Three New Approvals in Japan,https://www.merck.com/news/lynparza-olaparib-receives-three-new-approvals-in-japan/,2020-12-28,regulatory approval,
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19,https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-initial-doses-of-investigational-biological-therapy-for-the-treatment-of-patients-with-severe-and-critical-covid-19/,2020-12-23,clinical trial update,
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer,https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable/,2020-12-17,regulatory approval,
"KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study",https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-demonstrated-statistically-significant-improvement-in-overall-survival-progression-free-survival-and-objective-response-rate/,2020-12-16,clinical trial update,
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficien/,2020-12-11,regulatory approval,
Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference,https://www.merck.com/news/merck-to-present-at-the-2020-evercore-isi-3rd-annual-healthconx-virtual-conference/,2020-11-30,financial news,
"Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency",https://www.merck.com/news/merck-submits-applications-for-licensure-of-v114-the-companys-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-to-the-u-s-fda-and-european-medicines-agency/,2020-11-23,regulatory approval,
Merck to Acquire OncoImmune,https://www.merck.com/news/merck-to-acquire-oncoimmune/,2020-11-23,management update,
Merck Announces First-Quarter 2021 Dividend,https://www.merck.com/news/merck-announces-first-quarter-2021-dividend-2/,2020-11-17,financial news,
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1,https://www.merck.com/news/merck-advances-phase-3-trial-to-evaluate-investigational-islatravir-as-once-monthly-oral-prep-for-women-at-high-risk-for-acquiring-hiv-1/,2020-11-16,clinical trial update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10),https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-patients-with-locally-recurrent-unresectable-or-metastatic-triple%e2%80%91negative-breast-cancer-whose/,2020-11-13,regulatory approval,
"KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…",https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrated-statistically-significant-improvement-in-progression-free-survival-pfs-overall-survival-os-and-objective-response-rate/,2020-11-10,clinical trial update,
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue…,https://www.merck.com/news/merck-announces-keynote-598-trial-evaluating-keytruda-pembrolizumab-in-combination-with-ipilimumab-versus-keytruda-monotherapy-in-certain-patients-with-metastatic-non-small-cell-lung-cancer-to/,2020-11-09,clinical trial update,
LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC),https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-for-treatment-of-brca1-2-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc/,2020-11-05,regulatory approval,
LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer,https://www.merck.com/news/lynparza-olaparib-in-combination-with-bevacizumab-approved-in-the-eu-as-first-line-maintenance-treatment-for-hrd-positive-advanced-ovarian-cancer/,2020-11-05,regulatory approval,
Merck to Acquire VelosBio,https://www.merck.com/news/merck-to-acquire-velosbio/,2020-11-05,management update,
Merck Announces Third-Quarter 2020 Financial Results,https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/,2020-10-27,financial news,
"Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts",https://www.merck.com/news/merck-donates-500000-to-support-river-blindness-and-lymphatic-filariasis-elimination-efforts/,2020-10-22,Corporate Responsibility News,
Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020,https://www.merck.com/news/merck-to-present-new-data-from-its-extensive-infectious-diseases-and-vaccines-pipeline-and-portfolio-during-idweek-2020/,2020-10-21,clinical trial update,
"Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine",https://www.merck.com/news/merck-announces-positive-topline-results-from-two-additional-phase-3-adult-studies-evaluating-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine/,2020-10-20,clinical trial update,
Merck and Sanofi to Present Three New Studies Highlighting Combination Pediatric Vaccines at IDWeek 2020,https://www.merck.com/news/merck-and-sanofi-to-present-three-new-studies-highlighting-combination-pediatric-vaccines-at-idweek-2020/,2020-10-20,clinical trial update,
Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer,https://www.merck.com/news/merck-presents-three-year-survival-data-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-and-updated-phase-1-2-data-for-investigational-quavonlimab-mk-1308-in-combination-with-key/,2020-10-16,clinical trial update,
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL),https://www.merck.com/news/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl/,2020-10-15,regulatory approval,
Merck Issues 2019/2020 Corporate Responsibility Report,https://www.merck.com/news/merck-issues-2019-2020-corporate-responsibility-report/,2020-10-14,Corporate Responsibility News,
Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection,https://www.merck.com/news/merck-announces-week-96-data-from-phase-2b-study-evaluating-islatravir-in-combination-with-doravirine-in-adults-with-hiv-1-infection/,2020-10-08,clinical trial update,
"Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories",https://www.merck.com/news/merck-announces-retirement-of-dr-roger-m-perlmutter-dr-dean-y-li-appointed-as-president-merck-research-laboratories/,2020-10-02,management update,
Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020,https://www.merck.com/news/merck-to-present-new-data-from-the-companys-diverse-hiv-portfolio-and-pipeline-at-hiv-glasgow-2020/,2020-10-01,clinical trial update,
Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27,https://www.merck.com/news/merck-to-hold-third-quarter-2020-sales-and-earnings-conference-call-on-october-27/,2020-10-01,financial news,
Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day,https://www.merck.com/news/merck-animal-health-supports-rabies-elimination-by-2030-on-world-rabies-day/,2020-09-28,Corporate Responsibility News,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-locally-advanced-or-metastatic-esophageal-cancer/,2020-09-21,clinical trial update,
First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS ≥50%),https://www.merck.com/news/first-line-treatment-with-mercks-keytruda-pembrolizumab-doubled-five-year-survival-rate-31-9-versus-chemotherapy-16-3-in-certain-patients-with-metastatic-non-small-cell-lung-cance/,2020-09-21,clinical trial update,
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC),https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-for-treatment-of-brca1-2-metastatic-castration-resistant-prostate-cancer-mcrpc/,2020-09-21,regulatory approval,
LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer,https://www.merck.com/news/lynparza-olaparib-recommended-for-approval-in-eu-by-chmp-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer/,2020-09-21,regulatory approval,
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial,https://www.merck.com/news/lynparza-reduced-risk-of-death-by-31-vs-enzalutamide-or-abiraterone-for-men-with-brca1-2-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-who-progressed-following-enzalutamide-or-abirat/,2020-09-20,clinical trial update,
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020,https://www.merck.com/news/merck-presents-promising-new-data-for-three-investigational-medicines-from-diverse-and-expansive-oncology-pipeline-at-esmo-virtual-congress-2020/,2020-09-20,clinical trial update,
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020,https://www.merck.com/news/merck-and-eisai-present-first-time-data-from-two-studies-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-seven-different-tumor-types-at-esmo-virtual-congress-2020/,2020-09-20,clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma",https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-the-risk-of-distant-metastasis-or-death-by-40-versus-placebo-as-adjuvant-treatment-in-resected-high-risk-stage-iii-melanoma/,2020-09-19,clinical trial update,
LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer,https://www.merck.com/news/lynparza-olaparib-improved-median-progression-free-survival-to-over-four-and-a-half-years-compared-to-13-8-months-with-placebo-for-patients-with-brca-mutated-advanced-ovarian-cancer/,2020-09-18,clinical trial update,
Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020,https://www.merck.com/news/merck-to-hold-investor-briefing-following-esmo-virtual-congress-2020/,2020-09-16,financial news,
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-2020-cantor-fitzgerald-virtual-global-healthcare-conference/,2020-09-15,financial news,
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations,https://www.merck.com/news/seattle-genetics-and-merck-announce-two-strategic-oncology-collaborations/,2020-09-14,management update,
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-18th-annual-virtual-global-healthcare-conference/,2020-09-10,financial news,
"Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial",https://www.merck.com/news/merck-announces-positive-topline-results-from-two-phase-3-adult-studies-evaluating-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-including-pivotal-trial/,2020-09-09,clinical trial update,
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough,https://www.merck.com/news/mercks-gefapixant-45-mg-twice-daily-significantly-decreased-cough-frequency-compared-to-placebo-at-week-12-and-24-in-patients-with-refractory-or-unexplained-chronic-cough/,2020-09-08,clinical trial update,
Biopharma Leaders Unite to Stand with Science,https://www.merck.com/news/biopharma-leaders-unite-to-stand-with-science/,2020-09-08,Corporate News,
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference,https://www.merck.com/news/merck-to-present-at-the-citi-15th-annual-biopharma-virtual-conference/,2020-09-04,financial news,
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care,https://www.merck.com/news/new-scientific-data-at-the-esmo-virtual-congress-2020-reflect-mercks-commitment-to-advancing-cancer-research-and-care/,2020-09-02,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan,https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/,2020-08-24,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-overall-survival-and-progression-free-survival-compared-with-chemotherapy-in-locally-advanced-or/,2020-08-19,clinical trial update,
Merck Animal Health Completes Acquisition of IdentiGEN,https://www.merck.com/news/merck-animal-health-completes-acquisition-of-identigen/,2020-08-05,management update,
"Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)",https://www.merck.com/news/merck-and-hanmi-pharmaceutical-enter-into-licensing-agreement-to-develop-efinopegdutide-an-investigational-once-weekly-therapy-for-nonalcoholic-steatohepatitis-nash/,2020-08-04,management update,
Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio,https://www.merck.com/news/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio/,2020-08-03,management update,
Merck Announces Second-Quarter 2020 Financial Results,https://www.merck.com/news/merck-announces-second-quarter-2020-financial-results/,2020-07-31,financial news,
Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC),https://www.merck.com/news/merck-announces-two-us-regulatory-milestones-for-keytruda-pembrolizumab-in-triple-negative-breast-cancer-tnbc/,2020-07-30,regulatory approval,
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma,https://www.merck.com/news/fda-grants-breakthrough-therapy-designation-to-mercks-novel-hif-2%ce%b1-inhibitor-mk-6482-for-treatment-of-certain-patients-with-von-hippel-lindau-disease-associated-renal-cell-carcinoma/,2020-07-29,regulatory approval,
Merck Announces Fourth-Quarter 2020 Dividend,https://www.merck.com/news/merck-announces-fourth-quarter-2020-dividend/,2020-07-28,financial news,
FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat,https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-drug-application-for-vericiguat/,2020-07-16,regulatory approval,
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews,https://www.merck.com/news/merck-animal-health-receives-u-s-fda-approval-of-bravecto-fluralaner-monthly-chews/,2020-07-09,regulatory approval,
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-second-line-treatment-of-patients-with-relapsed-or-refractory-classical/,2020-07-09,regulatory approval,
Merck Announces Appointment of Organon & Co. General Counsel,https://www.merck.com/news/merck-announces-appointment-of-organon-co-general-counsel/,2020-07-08,management update,
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer,https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-for-germline-brca-mutated-metastatic-pancreatic-cancer/,2020-07-08,regulatory approval,
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma,https://www.merck.com/news/merck-and-eisai-receive-complete-response-letter-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma/,2020-07-08,regulatory approval,
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection,https://www.merck.com/news/merck-announces-new-analyses-showing-additional-safety-and-efficacy-data-for-investigational-islatravir-in-combination-with-doravirine-in-adults-with-hiv-1-infection/,2020-07-06,clinical trial update,
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals,https://www.merck.com/news/merck-animal-health-completes-acquisition-of-u-s-rights-to-sentinel-brand-of-combination-parasiticides-for-companion-animals/,2020-07-02,management update,
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction,https://www.merck.com/news/merck-and-ridgeback-bio-announce-closing-of-collaboration-and-licensing-transaction/,2020-07-01,management update,
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31,https://www.merck.com/news/merck-to-hold-second-quarter-2020-sales-and-earnings-conference-call-on-july-31/,2020-07-01,financial news,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer/,2020-06-29,regulatory approval,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-cscc-that-is-not-curable-by-surgery-or-radiat/,2020-06-24,regulatory approval,
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual,https://www.merck.com/news/merck-underscores-commitment-to-hiv-with-new-data-analyses-to-be-presented-at-aids-2020-virtual/,2020-06-24,clinical trial update,
"Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults",https://www.merck.com/news/merck-announces-that-v114-its-investigational-15-valent-pneumococcal-conjugate-vaccine-met-safety-and-immunogenicity-objectives-in-initial-phase-3-studies-in-adults/,2020-06-22,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10),https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-for-second-line-treatment-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-whose-tumors-express-pd-l1/,2020-06-22,regulatory approval,
Merck Completes Acquisition of Themis,https://www.merck.com/news/merck-completes-acquisition-of-themis/,2020-06-19,management update,
Merck Animal Health Completes Acquisition of Quantified Ag®,https://www.merck.com/news/merck-animal-health-completes-acquisition-of-quantified-ag/,2020-06-17,management update,
"FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type",https://www.merck.com/news/fda-approves-second-biomarker-based-indication-for-mercks-keytruda-pembrolizumab-regardless-of-tumor-type/,2020-06-17,regulatory approval,
Merck Prices $4.5 Billion Debt Offering,https://www.merck.com/news/merck-prices-4-5-billion-debt-offering/,2020-06-17,financial news,
Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease,https://www.merck.com/news/merck-and-pfizers-sglt2-inhibitor-steglatro-ertugliflozin-meets-primary-endpoint-in-vertis-cv-trial-for-patients-with-type-2-diabetes-and-atherosclerotic-cardiovascular-disease/,2020-06-16,clinical trial update,
"Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities",https://www.merck.com/news/merck-announces-call-for-proposals-for-second-cohort-of-safer-childbirth-cities-expanding-maternal-health-support-across-us-cities/,2020-06-15,Corporate Responsibility News,
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers,https://www.merck.com/news/fda-approves-mercks-gardasil-9-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers/,2020-06-12,regulatory approval,
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma,https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-361-trial-evaluating-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-in-patients-with-advanced-or-metastatic-urothelial-carc/,2020-06-09T00:00:00,clinical trial update,
"FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)",https://www.merck.com/news/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp/,2020-06-05T00:00:00,regulatory approval,
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer,https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-for-first-line-maintenance-treatment-of-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer/,2020-06-01T00:00:00,regulatory approval,
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma,https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-demonstrated-clinically-meaningful-tumor-response-rates-in-unresectable-hepatocellular-carcinoma-and-advanced-renal-cell-carc/,2020-05-28T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-superior-to-standard-of-care-chemotherapy-in-patients-with-msi-h-colorectal-cancer/,2020-05-28T00:00:00,clinical trial update,
Merck Announces Third-Quarter 2020 Dividend,https://www.merck.com/news/merck-announces-third-quarter-2020-dividend/,2020-05-26T00:00:00,financial news,
"Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801",https://www.merck.com/news/merck-and-ridgeback-bio-collaborate-to-advance-development-of-novel-antiviral-candidate-eidd-2801/,2020-05-26T00:00:00,clinical trial update,
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2,https://www.merck.com/news/iavi-and-merck-collaborate-to-develop-vaccine-against-sars-cov-2/,2020-05-26T00:00:00,clinical trial update,
Merck to Acquire Themis,https://www.merck.com/news/merck-to-acquire-themis/,2020-05-26T00:00:00,management update,
Merck to Announce Multiple Scientific Efforts to Combat COVID-19,https://www.merck.com/news/merck-to-announce-multiple-scientific-efforts-to-combat-covid-19/,2020-05-26T00:00:00,management update,
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone,https://www.merck.com/news/lynparza-olaparib-approved-by-fda-for-treatment-of-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer-that-has-progressed-following-prior-treatment-with-enzalutamide-or-abiratero/,2020-05-20T00:00:00,regulatory approval,
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship,https://www.merck.com/news/infectious-disease-connect-and-ilum-health-solutions-combine-to-advance-precision-treatment-of-infectious-diseases-and-antimicrobial-stewardship/,2020-05-19T00:00:00,management update,
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer,https://www.merck.com/news/merck-announces-appointment-of-organon-co-chief-financial-officer-and-chief-information-officer/,2020-05-18T00:00:00,management update,
Merck to Present at the UBS Virtual Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-ubs-virtual-global-healthcare-conference/,2020-05-14T00:00:00,management update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-demonstrated-statistically-significant-improvement-in-progression-free-survival-versus-chemotherapy-in-certain-patients-with-metastatic/,2020-05-13T00:00:00,clinical trial update,
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma,https://www.merck.com/news/mercks-novel-hif-2%ce%b1-inhibitor-showed-an-objective-response-rate-of-nearly-30-in-patients-with-von-hippel-lindau-vhl-disease-associated-clear-cell-renal-cell-carcinoma/,2020-05-13T00:00:00,clinical trial update,
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC,https://www.merck.com/news/new-combination-data-for-mercks-keytruda-pembrolizumab-demonstrated-clinical-benefit-in-stage-iii-non-small-cell-lung-cancer-nsclc-and-reinforce-long-term-survival-in-metastatic-nsc/,2020-05-13T00:00:00,clinical trial update,
"Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial",https://www.merck.com/news/mercks-keytruda-pembrolizumab-superior-to-brentuximab-vedotin-bv-a-standard-of-care-in-patients-with-classical-hodgkin-lymphoma-chl-in-head-to-head-phase-3-trial/,2020-05-13T00:00:00,clinical trial update,
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals,https://www.merck.com/news/merck-animal-health-to-acquire-u-s-rights-to-sentinel-brand-of-combination-parasiticides-for-companion-animals/,2020-05-13T00:00:00,management update,
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer,https://www.merck.com/news/lynparza-olaparib-approved-by-fda-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer/,2020-05-08T00:00:00,regulatory approval,
Merck Announces Virtual 2020 Annual Shareholders Meeting,https://www.merck.com/news/merck-announces-virtual-2020-annual-shareholders-meeting/,2020-05-08T00:00:00,management update,
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications,https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-for-all-approved-adult-indications/,2020-04-28T00:00:00,regulatory approval,
Merck Announces First-Quarter 2020 Financial Results,https://www.merck.com/news/merck-announces-first-quarter-2020-financial-results/,2020-04-28T00:00:00,financial news,
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I,https://www.merck.com/news/first-clinical-outcomes-evaluating-six-week-dosing-schedule-for-mercks-keytruda-pembrolizumab-presented-at-aacr-virtual-annual-meeting-i/,2020-04-27T00:00:00,clinical trial update,
Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers,https://www.merck.com/news/merck-and-institute-for-systems-biology-collaborate-to-define-molecular-mechanisms-of-sars-cov-2-infection-and-identify-potential-prognostic-biomarkers/,2020-04-27T00:00:00,clinical trial update,
LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer,https://www.merck.com/news/lynparza-olaparib-demonstrated-overall-survival-benefit-in-phase-3-profound-trial-for-brca1-2-or-atm-mutated-metastatic-castration-resistant-prostate-cancer/,2020-04-24T00:00:00,clinical trial update,
Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule,https://www.merck.com/news/merck-resubmits-supplemental-biologics-license-applications-sblas-for-keytruda-pembrolizumab-six-week-dosing-schedule/,2020-04-23T00:00:00,regulatory approval,
Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts,https://www.merck.com/news/merck-broadens-patient-support-and-assistance-programs-as-part-of-overall-covid-19-relief-efforts/,2020-04-21T00:00:00,management update,
"Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)",https://www.merck.com/news/merck-announces-us-launch-of-ontruzant-trastuzumab-dttb-a-biosimilar-of-herceptin-trastuzumab/,2020-04-15T00:00:00,commercialized drug update,
"KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas",https://www.merck.com/news/koselugo-selumetinib-approved-by-fda-for-pediatric-patients-two-years-and-older-with-neurofibromatosis-type-1-and-symptomatic-inoperable-plexiform-neurofibromas/,2020-04-13T00:00:00,regulatory approval,
Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic,https://www.merck.com/news/merck-announces-3m-commitment-to-address-critical-maternal-health-needs-during-covid-19-pandemic/,2020-04-09T00:00:00,management update,
"Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type",https://www.merck.com/news/merck-receives-priority-review-from-fda-for-second-application-for-keytruda-pembrolizumab-based-on-biomarker-regardless-of-tumor-type/,2020-04-07T00:00:00,regulatory approval,
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer,https://www.merck.com/news/merck-announces-keytruda-pembrolizumab-significantly-improved-progression-free-survival-as-first-line-treatment-for-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficien/,2020-04-02T00:00:00,clinical trial update,
Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28,https://www.merck.com/news/merck-to-hold-first-quarter-2020-sales-and-earnings-conference-call-on-april-28/,2020-04-02T00:00:00,financial news,
"Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic",https://www.merck.com/news/medical-professionals-across-merck-co-inc-pfizer-inc-and-eli-lilly-and-company-activate-to-support-health-systems-first-responders-and-patients-amid-covid-19-pandemic/,2020-04-01T00:00:00,management update,
"Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies",https://www.merck.com/news/investigational-drug-vericiguat-significantly-reduced-the-risk-of-the-composite-endpoint-of-heart-failure-hospitalization-or-cardiovascular-death-compared-to-placebo-when-given-in-combination-with-a/,2020-03-28T00:00:00,clinical trial update,
"Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response",https://www.merck.com/news/merck-to-donate-300000-masks-to-new-jersey-for-covid-19-emergency-response/,2020-03-25T00:00:00,management update,
Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City,https://www.merck.com/news/merck-donates-a-half-a-million-masks-to-support-covid-19-emergency-response-in-new-york-city/,2020-03-22T00:00:00,management update,
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer,https://www.merck.com/news/merck-recommends-rejection-of-trc-capitals-mini-tender-offer/,2020-03-20T00:00:00,management update,
"Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough",https://www.merck.com/news/merck-announces-top-line-results-from-phase-3-trials-evaluating-gefapixant-an-investigational-treatment-for-refractory-or-unexplained-chronic-cough/,2020-03-17T00:00:00,clinical trial update,
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer,https://www.merck.com/news/update-on-phase-3-gy004-for-cediranib-and-lynparza-olaparib-in-platinum-sensitive-relapsed-ovarian-cancer/,2020-03-12T00:00:00,clinical trial update,
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite,https://www.merck.com/news/scientists-from-merck-and-the-walter-and-eliza-hall-institute-of-medical-research-discover-novel-class-of-candidate-anti-malaria-agents-that-block-multiple-stages-of-the-lifecycle-of-the-parasite/,2020-03-04T00:00:00,clinical trial update,
Merck Announces New Data from Broad HIV Program at CROI 2020,https://www.merck.com/news/merck-announces-new-data-from-broad-hiv-program-at-croi-2020/,2020-03-02T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL),https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-progression-free-survival-compared-with-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-ch/,2020-03-02T00:00:00,clinical trial update,
Merck to Present at the Cowen Health Care Conference,https://www.merck.com/news/merck-to-present-at-the-cowen-health-care-conference/,2020-02-27T00:00:00,management update,
Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule,https://www.merck.com/news/merck-receives-complete-response-letter-from-the-us-fda-for-supplemental-biologics-license-applications-sblas-for-keytruda-pembrolizumab-six-week-dosing-schedule/,2020-02-18T00:00:00,regulatory approval,
"ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification",https://www.merck.com/news/ervebo-ebola-zaire-vaccine-live-now-registered-in-four-african-countries-within-90-days-of-reference-country-approval-and-who-prequalification/,2020-02-14T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC),https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-treatment-for-metastatic-triple-negative-breast-ca/,2020-02-12T00:00:00,clinical trial update,
Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results,https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2019-financial-results/,2020-02-05T00:00:00,financial news,
"Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”)",https://www.merck.com/news/merck-to-focus-on-key-growth-pillars-through-spinoff-of-womens-health-trusted-legacy-brands-and-biosimilars-products-into-new-company-newco/,2020-02-05T00:00:00,management update,
"FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)",https://www.merck.com/news/fda-accepts-for-review-supplemental-new-drug-application-snda-for-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associat/,2020-02-03T00:00:00,regulatory approval,
Merck Receives Approval for BELSOMRA® (suvorexant) C-IV Label Update to Include Findings from Study of Insomnia in Patients with Mild-to-Moderate Alzheimer’s Disease,https://www.merck.com/news/merck-receives-approval-for-belsomra-suvorexant-c-iv-label-update-to-include-findings-from-study-of-insomnia-in-patients-with-mild-to-moderate-alzheimers-disease/,2020-02-03T00:00:00,regulatory approval,
Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors,https://www.merck.com/news/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors/,2020-01-31T00:00:00,management update,
Merck Announces Second-Quarter 2020 Dividend,https://www.merck.com/news/merck-announces-second-quarter-2020-dividend/,2020-01-28T00:00:00,financial news,
FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older,https://www.merck.com/news/fda-approves-mercks-dificid-fidaxomicin-to-treat-clostridioides-difficile-in-children-aged-six-months-and-older/,2020-01-27T00:00:00,regulatory approval,
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review,https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/,2020-01-21T00:00:00,regulatory approval,
Merck Completes Acquisition of ArQule,https://www.merck.com/news/merck-completes-acquisition-of-arqule/,2020-01-16T00:00:00,management update,
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review,https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-as-first-line-maintenance-with-bevacizumab-in-advanced-ovarian-cancer-and-grants-priority-review/,2020-01-13T00:00:00,regulatory approval,
"FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy",https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-with-or-without-papillary-tumors-wh/,2020-01-08T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-progression-free-survival-compared-to-chemotherapy-alone-as-first-line-treatment-for-extensive-st/,2020-01-06T00:00:00,clinical trial update,
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex,https://www.merck.com/news/merck-establishes-strategic-oncology-collaboration-with-taiho-and-astex/,2020-01-06T00:00:00,management update,
Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5,https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2019-sales-and-earnings-conference-call-on-february-5/,2020-01-03T00:00:00,financial news,
Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/,2020-01-02T00:00:00,management update,
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer,https://www.merck.com/news/lynparza-olaparib-approved-by-fda-as-first-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer/,2019-12-30T00:00:00,regulatory approval,
"Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)",https://www.merck.com/news/merck-announces-fda-approval-for-ervebo-ebola-zaire-vaccine-live/,2019-12-20T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer,https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/,2019-12-20T00:00:00,regulatory approval,
"FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC",https://www.merck.com/news/fda-oncologic-drugs-advisory-committee-odac-recommends-keytruda-pembrolizumab-for-the-treatment-of-certain-patients-with-high-risk-non-muscle-invasive-bladder-cancer-nmibc/,2019-12-17T00:00:00,regulatory approval,
Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare,https://www.merck.com/news/merck-animal-health-completes-acquisition-of-vaki-to-further-broaden-its-leadership-position-in-aquaculture-to-advance-fish-health-and-welfare/,2019-12-17T00:00:00,management update,
LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemotherapy,https://www.merck.com/news/lynparza-olaparib-recommended-by-fda-advisory-committee-for-first-line-maintenance-therapy-in-germline-brca-mutated-metastatic-pancreatic-cancer-that-has-not-progressed-on-platinum-based-chemo/,2019-12-17T00:00:00,regulatory approval,
Merck Begins Tender Offer to Acquire ArQule,https://www.merck.com/news/merck-begins-tender-offer-to-acquire-arqule/,2019-12-17T00:00:00,management update,
"Merck Receives Positive EU CHMP Opinion for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Infections Due to Aerobic  Gram-Negative Organisms in Adults with Limited Treatment Options",https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-infections-due-to-aerobic-gram-negative-organisms-in-adults-with-limited-tre/,2019-12-16T00:00:00,regulatory approval,
Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status,https://www.merck.com/news/data-from-exploratory-analysis-show-mercks-keytruda-pembrolizumab-improved-overall-survival-as-monotherapy-for-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-regard/,2019-12-12T00:00:00,clinical trial update,
"Merck to Acquire ArQule, Advancing Leadership in Oncology",https://www.merck.com/news/merck-to-acquire-arqule-advancing-leadership-in-oncology/,2019-12-09T00:00:00,management update,
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer,https://www.merck.com/news/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer/,2019-12-05T00:00:00,regulatory approval,
Merck to Present at the Evercore ISI HealthCONx Conference 2019,https://www.merck.com/news/merck-to-present-at-the-evercore-isi-healthconx-conference-2019/,2019-12-02T00:00:00,management update,
"FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)",https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-certain-patients-with-high-risk-non-muscle-invasive-bladder-cance/,2019-12-02T00:00:00,regulatory approval,
Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy,https://www.merck.com/news/mercks-keytruda-pembrolizumab-now-approved-in-china-for-first-line-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-nsclc-in-combination-with-chemotherapy/,2019-11-26T00:00:00,regulatory approval,
European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC),https://www.merck.com/news/european-commission-approves-two-new-regimens-of-mercks-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma/,2019-11-20T00:00:00,regulatory approval,
Merck Announces First-Quarter 2020 Dividend,https://www.merck.com/news/merck-announces-first-quarter-2020-dividend/,2019-11-19T00:00:00,financial news,
Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure,https://www.merck.com/news/merck-and-bayers-investigational-drug-vericiguat-meets-primary-endpoint-in-phase-3-study-of-patients-with-worsening-chronic-heart-failure/,2019-11-18T00:00:00,clinical trial update,
BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration,https://www.merck.com/news/bravecto-plus-fluralaner-and-moxidectin-topical-solution-for-cats-receives-approval-from-us-food-and-drug-administration/,2019-11-15T00:00:00,regulatory approval,
US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review,https://www.merck.com/news/us-fda-accepts-regulatory-submission-of-new-drug-application-for-selumetinib-in-neurofibromatosis-type-1-nf1-and-grants-priority-review/,2019-11-14T00:00:00,regulatory approval,
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union,https://www.merck.com/news/mercks-ervebo-ebola-zaire-vaccine-rvsv%ce%b4g-zebov-gp-live-granted-conditional-approval-in-the-european-union/,2019-11-11T00:00:00,regulatory approval,
Merck to Present New Data from its HIV Portfolio at the 17th European AIDS Conference,https://www.merck.com/news/merck-to-present-new-data-from-its-hiv-portfolio-at-the-17th-european-aids-conference/,2019-11-06T00:00:00,clinical trial update,
Merck Announces Third-Quarter 2019 Financial Results,https://www.merck.com/news/merck-announces-third-quarter-2019-financial-results/,2019-10-29T00:00:00,financial news,
Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease,https://www.merck.com/news/merck-receives-eu-chmp-positive-opinion-for-investigational-v920-ebola-zaire-vaccine-for-protection-against-ebola-virus-disease/,2019-10-18T00:00:00,regulatory approval,
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma,https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma/,2019-10-18T00:00:00,regulatory approval,
Merck Issues 2018/2019 Corporate Responsibility Report,https://www.merck.com/news/merck-issues-2018-2019-corporate-responsibility-report/,2019-10-08T00:00:00,management update,
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1,https://www.merck.com/news/mercks-keytruda-pembrolizumab-now-approved-as-monotherapy-in-china-for-first-line-treatment-of-certain-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-p/,2019-10-02T00:00:00,regulatory approval,
FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections,https://www.merck.com/news/fda-accepts-two-applications-for-mercks-dificid-fidaxomicin-to-treat-children-aged-six-months-up-to-18-years-with-clostridium-difficile-infections/,2019-10-02T00:00:00,regulatory approval,
Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29,https://www.merck.com/news/merck-to-hold-third-quarter-2019-sales-and-earnings-conference-call-on-october-29/,2019-10-01T00:00:00,financial news,
LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months),https://www.merck.com/news/lynparza-olaparib-more-than-doubled-median-radiographic-progression-free-survival-rpfs-in-brca1-2-or-atm-metastatic-castration-resistant-prostate-cancer-vs-standard-of-care-7-4-vs-3-6-mon/,2019-09-30T00:00:00,clinical trial update,
Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference,https://www.merck.com/news/merck-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference/,2019-09-30T00:00:00,management update,
"Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint",https://www.merck.com/news/pivotal-restore-imi-2-phase-3-study-of-mercks-recarbrio-imipenem-cilastatin-and-relebactam-in-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp-met-prim/,2019-09-30T00:00:00,clinical trial update,
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC),https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-statistically-significant-increase-in-pathological-complete-response-versus-chemotherapy-as-neoadjuvant-therapy-in-early-stage-t/,2019-09-29T00:00:00,clinical trial update,
Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress,https://www.merck.com/news/final-study-results-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-treatment-in-advanced-endometrial-cancer-presented-at-esmo-2019-congress/,2019-09-29T00:00:00,clinical trial update,
